Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use

ABSTRACT

The presently disclosed inventive concept(s) include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and α 2 -antiplasmin and abnormal cell proliferation. The presently disclosed inventive concept(s) also include substrates of APCE and FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed inventive concept(s) further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma α 2 -antiplasmin and to methods of treating conditions involving abnormal cell proliferation such as cancers.

CROSS-REFERENCE TO RELATED APPLICATIONS/INCORPORATION BY REFERENCE STATEMENT

The present application is a continuation of U.S. Ser. No. 14/592,178, filed Jan. 8, 2015; which is a continuation of U.S. Ser. No. 12/969,161, filed Dec. 15, 2010, now U.S. Pat. No. 8,933,201, issued Jan. 13, 2015; which claims the benefit under 35 USC §119(e) of U.S. Provisional Application Ser. No. 61/286,558, filed Dec. 15, 2009. The '161 application is also a continuation-in-part of U.S. Ser. No. 11/811,002, filed Jun. 6, 2007, now abandoned; which claims the benefit under 35 USC §119(e) of U.S. Provisional Application Ser. No. 60/811,568, filed Jun. 7, 2006, and U.S. Provisional Application Ser. No. 60/836,365, filed Aug. 8, 2006. The entire contents of each of the above-referenced patents and applications are hereby expressly incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under Grant HL072995 awarded by the National Institutes of Health, U.S.A., and Grant W81XWH-08-1-0588 awarded by the Army Research Office, U.S.A. The government has certain rights in the invention.

BACKGROUND

The presently disclosed inventive concept(s) are related to, but not limited to, substrates and inhibitors of α₂-antiplasmin cleaving enzyme and fibroblast activation protein-alpha and to screening methods for identifying such inhibitors, and to methods for treating conditions involving fibrin and α₂-antiplasmin, including plaque and clot formation, atherosclerosis and cancers involving fibroblast activation protein.

α₂-Antiplasmin (α₂AP) is a glycoprotein in blood plasma that rapidly and specifically inhibits the enzyme, plasmin, which digests blood clots, whether presenting early as intravascular platelet-fibrin deposits or as partially or completely occlusive thrombi. Similarly, plasmin and α₂AP activities are important to the development and survival of fibrin as occurs in inflammation, wound healing and virtually all forms of cancer and its metastases.

Human α₂-antiplasmin (α₂AP), also known as α₂-plasmin inhibitor, is the main inhibitor of plasmin. Plasmin plays a critical role in fibrin proteolysis and tissue remodeling. The physiologic relevance of plasmin inhibition by α₂AP to blood clotting and fibrinolytic homeostasis is supported by the following observations: (1) the rate of free plasmin inactivation by circulating α₂AP is much faster than fibrin(ogen) digestion by plasmin, thereby eliminating the possibility of a systemic lytic state and consequent bleeding; (2) α₂AP is cross-linked to forming fibrin by activated blood clotting factor XIII (FXIIIa) and inhibits plasmin-mediated lysis in direct proportion to the amount incorporated; and (3) patients with homozygous α₂AP deficiency manifest serious hemorrhagic tendencies, while heterozygotes tend to bleed only after major trauma or surgery. Human α₂AP is synthesized primarily in the liver, and during circulation in plasma, the secreted precursive form, Met-α₂-antiplasmin (Met-α₂AP), a 464-residue protein having methionine as the N-terminus, undergoes proteolytic cleavage between Pro12 and Asn13 (the P₁-P₁′ scissile bond) to yield Asn-α₂-antiplasmin (Asn-α₂AP), a 452-residue version with asparagine as the N-terminus. Met-α₂AP accounts for approximately 30% of circulating α₂AP, and Asn-α₂AP accounts for approximately 70%.

When the Met-form of α₂AP was found in plasma and its gene sequenced, there initially appeared to be a discrepancy in one of the nucleotides encoding the sixth amino acid. Two groups found a cytidine (C) resulting in Arg as the sixth amino acid, and one group found thymidine (T), resulting in Trp at that position. It was suggested that the difference was due to one group having used liver carcinoma cells as a source of DNA, while the other two groups used normal cells. It has now been determined that both Arg6 and Trp6 forms of Met-α₂AP exist in normal human plasma samples. An investigation of a mutant α₂AP in a family with bleeding tendencies identified the mutation responsible for the ineffective α₂AP along with three polymorphisms in the α₂AP gene including this C/T single nucleotide polymorphism (SNP); this study examined 30 normal blood donors and reported an allelic frequency of 0.81/0.19 for the C/T SNP. No larger studies of a normal population have been done to examine the frequency of homozygotes and heterozygotes, or whether genotype might affect ratios of Met- to Asn-α₂AP in plasma. The Arg6Trp SNP was apparently assumed to be a silent polymorphism, but biochemical examination of the two polymorphic forms of Met-α₂AP on yielding the derivative form, Asn-α₂AP, its incorporation into fibrin and the impact on fibrinolysis have never been assessed prior to the present work.

We discovered antiplasmin-cleaving enzyme (APCE) in human plasma and showed that it is a soluble isoform or derivative of fibroblast activation protein-alpha (FAP), the latter being a type II integral membrane protein, which is predicted to have its first six N-terminal residues within fibroblast cytoplasm, followed by a 20-residue transmembrane domain, and then a 734-residue extracellular C-terminal catalytic domain. Like APCE, FAP is also a prolyl-specific enzyme that exhibits both endopeptidase and dipeptidyl peptidase activities. FAP is expressed by activated fibroblasts during embryogenesis, wound healing and expansion of epithelial-derived cancers, but not by normal tissues. We have also reported that FAP and APCE are essentially identical in amino acid sequence, except that APCE lacks the first 23 amino terminal residues of FAP, but otherwise the two molecules have essentially identical physico-chemical properties.

Specific inhibitors of APCE which result in enhanced endogenous fibrinolytic dispersion of intravascular platelet-fibrin thrombi, or that block FAP and its proteolysis of extracellular matrix during cancers expansion or other conditions of abnormal cell proliferation are desirable and are objects of the presently disclosed inventive concept(s).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a non-limiting exemplary sequence of a FRET peptide (SEQ ID NO:1).

FIG. 2 shows various substitutions which could be made in various positions of a FRET peptide of the present disclosure (SEQ ID NO:2).

FIG. 3 shows an alternative embodiment of an amino acid sequence (SEQ ID NO:3) comprising a portion of a FRET peptide or inhibitor of the presently disclosed inventive concept(s).

FIG. 4A shows a schematic of a structure of acetyl-arg-8-amino-3,6-dioxaoctanoic acid-D-ala-L-boroPro, an exemplary inhibitor compound of the presently disclosed inventive concept(s). FIG. 4B illustrates the isostere structure with a methylene group replacement of the arg carbonyl.

FIG. 5 shows structures which demonstrate several “proline analogs” which can be used in the compounds of the presently disclosed inventive concept(s).

FIG. 6 is a graph showing cell surface FAP activity of fibroblasts. W138 Cells were seeded into opaque black 96 well cell culture plates and grown to confluency. Cells were washed with Hanks Balanced Salt Solution after which either the inhibitor compound Ac-Arg-(8-amino-3,6-dioxaoctanoyl)-D-Ala-L-boroPro, or buffer, was added. The FAP substrate, Ac-R-peg-G-P-AMC, was added and fluorescence was measured with time. The inhibitor was added to one set of cells 2 hours after substrate addition (see arrow). O.D. 360/460 was converted to APCE Units using a standard curve. As can be seen from the flattening of the line marked by triangles, the inhibitor inhibited cell surface FAP immediately.

FIG. 7 is a graph showing cell surface FAP activity of breast cancer cells. MDA-MB-435 cells were seeded into opaque black 96 well cell culture plates and grown to confluency. Cells were washed with Hanks Balanced Salt solution after which either the inhibitor compound Ac-Arg-(8-amino-3,6-dioxaoctanoyl)-D-Ala-L-boroPro, or buffer, was added. The FAP substrate, Ac-R-peg-G-P-AMC, was added and fluorescence measured with time. O.D. 360/460 was converted to APCE Units using a standard curve.

DETAILED DESCRIPTION

The presently disclosed inventive concept(s) include, but are not limited to, inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein-alpha (FAP) for use in various therapies related to fibrin and α₂-antiplasmin and FAP, and to substrates of APCE or FAP, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed inventive concept(s) also include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders and conditions involving abnormal cell proliferation.

The presently disclosed inventive concept(s) are directed to methods and compounds for treating conditions characterized by abnormal cell proliferation, including, but not limited to, cancer and metastasis by using the inhibitors of the present disclosure to inhibit the enzymatic activity of fibroblast activation protein-alpha (FAP). In one embodiment, the presently disclosed inventive concept(s) provide a method for treating a subject having a condition characterized by abnormal mammalian cell proliferation comprising administering to a subject in need of such treatment, an agent in an amount effective to inhibit the proliferation, wherein the agent is a compound having Formula I as described herein.

Human Met-α₂AP is a physiologically important substrate of APCE, since proteolytic cleavage between Pro12-Asn13 yields the more active derivative, Asn-α₂AP, which becomes cross-linked significantly faster to fibrin by FXIIIa than Met-α₂AP, and, as a consequence, enhances the resistance of fibrin to digestion by plasmin. Since human APCE augments the inhibition of fibrinolysis by increasing the availability of the faster cross-linking form (i.e., Asn-α₂AP), potent and selective inhibitors of APCE which have been discovered as described herein allow titration of Asn-α₂AP production to lower in vivo levels, and thereby enhance both endogenous and exogenous fibrinolysis (fibrin removal). Bleeding complications using the treatments described herein are unlikely, based on the observation that persons heterozygous for α₂AP deficiency have minimal hemorrhagic risk. Hence, a window of safety exists for lowering α₂AP function in healthy persons. Particularly in clinical situations where fibrin formation is likely, APCE inhibitors will result in decreased amount of Asn-α₂AP available for cross-linking to fibrin as thrombi develop or inflammation progresses. Then endogenous levels of generated plasmin, or plasmin produced by administering small amounts of a plasminogen activator, might be sufficient to effect fibrin removal so that vessel patency and organ function are maintained and bleeding risk is minimized. As noted above, APCE cleaves Met α₂AP to the derivative Asn α₂AP, which is more efficiently incorporated into fibrin and consequently makes it strikingly resistant to plasmin digestion. APCE thus represents a new target for pharmacologic modulation and inhibition of the fibrinolytic system, since less generation and therefore less incorporation of Asn-α₂AP results in a more rapid removal of fibrin by plasmin during atherogenesis, thrombosis, and inflammatory states.

The presently disclosed inventive concept(s) include inhibitors of antiplasmin cleaving enzyme for use in various therapies related to fibrin and α₂-antiplasmin, and to substrates of APCE, which may be used, for example, in screening methods for identifying such inhibitors. The presently disclosed inventive concept(s) further include, but are not limited to, methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the ratios of types of plasma α₂-antiplasmin and to methods of treating abnormal cell proliferation conditions involving FAP. With respect to FAP, inhibition of this enzyme will limit or obviate the ability of epithelial-derived cancers to invade surrounding extracellular matrix, thereby limiting the cancer's spread and allowing more effective use of chemotherapy or radiation therapy.

In one embodiment, inhibition of APCE is defined herein as at least 50% inhibition of activity of APCE, for example, at an inhibitor concentration of 20 μM. Examples of the inhibitors contemplated herein include, for example: Arg-8-amino-3,6-dioxaoctanoic acid-Gly-boroPro and Arg-8-amino-3,6-dioxaoctanoic acid-d-Ala-boroPro. Groups which may substitute for boro-Pro (boronyl proline), include, for example, other boronic acid derivatives, carbocyclic groups, heterocyclic groups, carbonitriles, carboxynitriles, or nitrilic-containing compounds), where the Arg (or other positively-charged N-terminal amino acid) may or may not be blocked with a protecting group such as, but not limited to, succinyl, acetyl, benzoyl, or benzyloxycarbonyl or other protecting group commonly used for blocking peptides from attack by proteases.

In certain non-limiting embodiments, the inhibitors of APCE of the presently disclosed inventive concept(s) also inhibit FAP and can be used in treatment of various cancers, or other FAP-related conditions, or other conditions involving abnormal cell proliferation as described in further detail below. Without wishing to be bound by theory, the inhibitors described herein are effective, highly efficient inhibitors which prevent, inhibit, and/or reduce the expansion of extracellular space by digestion of FAP's substrate proteins, e.g., type I collagen within the extracellular matrix (ECM). This will then abrogate subsequent movement of activated fibroblasts for remodeling ECM space with new stromal scaffolding to which malignant cells adhere for migration and mitosis. As a consequence, the neoplasm will then atrophy and undergo necrosis, or be arrested to an extent that radiation and/or chemotherapy measures, such as (but not limited to) at lower than standard doses, will eradicate the malignancy. Previously a number of studies of metastatic cancer indicated that Val-boroPro, a dipeptide containing a boronic acid derivative of proline (for example as described in U.S. Pat. No. 7,399,869), inhibits FAP, and as a consequence, cancer growth. Unfortunately, however, Val-boroPro also non-selectively inhibits most prolylpeptidases such as dipeptidyl peptidases (such as DPPIV) and up-regulates cytokine and chemokine 5 activities. Several other prolyl boronic acid derivatives have been developed and reported as putative selective inhibitors for FAP, but their instability in aqueous environments at physiologic pH and their non-specific reactivities with other enzymes due to the electrophilic property of boronic acid has complicated progress. Stable and specific inhibitors can also be useful in furthering the understanding of the relationship between APCE activity and fibrin clot lysis or FAP activity and malignant tumor growth. Therefore, in accordance with the presently disclosed inventive concept(s), we have developed specific inhibitors of APCE (and also of FAP as a consequence of APCE's virtual identicality to FAP). These include, for example, synthetic peptides composed of selected natural and unnatural amino acids within the P₇-P₁ sequence of APCE's physiologic substrate, namely, precursive α₂-antiplasmin, having Met as its amino-terminal residue.

Prior to the presently disclosed inventive concept(s), there were no effective inhibitors of APCE or FAP that have sufficient specificity to allow exploration of effects on the pathogenesis or therapy of chronic diseases such as atherosclerosis or a variety of different cancers. For example, various dipeptide boronyl proline constructs (e.g., “val-boroPro”) have been used in efforts to inhibit FAP, but as noted above these also inhibited several other prolyl peptidases, some of the latter being critical for important metabolic functions. Moreover, the design of these amino acid boro-proline inhibitors did not prevent or slow their cyclization and inactivation that occurs within a few minutes in aqueous environments. The inhibitors of the presently disclosed inventive concept(s) avoid these pitfalls.

Further, the presently disclosed inhibitor compounds with high specificity for FAP/APCE can be used in in vitro assays based on cancer cell lines to determine the role of FAP at various stages of pathogenesis of FAP-related cancers. The exact mode of how FAP operates in specific cancer etiologies is still under study and an inhibitor molecule for selectively inhibiting FAP can be most useful.

Modulation of α₂-Antiplasmin Ratio

Asn-α₂AP crosslinks to fibrin at a rate of about 13-fold faster than Met-α₂AP. A faster crosslink rate results in a greater number of antiplasmin molecules bound to newly formed fibrin and a resultant enhanced resistance to fibrinolysis. Inhibition of plasma APCE can thus decrease the number of antiplasmin molecules crosslinked thereby resulting in clots that are more easily removed during fibrinolysis. Therefore an inhibitor specific for APCE can be used to regulate fibrinolysis. As noted above, human Met-α₂AP exists in two polymorphic forms at position six in the mature sequence, with arginine predominant and tryptophan accounting for a lesser percentage. It has been discovered that inhibition of APCE can alter the α₂AP ratio from approximately 30% Met-α₂AP:70% Asn-α₂P to approximately 60%-70% Met-α₂AP:40%-30% Asn-α₂AP in the plasma.

Previously, (e.g., see U.S. Publication No. 2008/0057491) we determined the prevalence of the polymorphism in a much larger normal population and then assessed whether it relates to the inhibitory function of α₂AP. We obtained results regarding (1) genotype frequencies of the Arg6Trp SNP in Met-α₂AP; (2) how each form affects susceptibility to cleavage by APCE; (3) the percent of Met-α₂AP in plasma for each of the two polymorphisms; (4) plasma clot lysis times in relation to genotype; and (5) evidence that removal of circulating APCE prevents conversion of Met- to Asn-α₂AP.

The relationship between RR, RW and WW genotypes and corresponding Met-α₂AP/Asn-α₂AP ratios raised the possibility that the latter would impact individuals' fibrinolytic activities so that over the course of one's life, vulnerability of intravascularly generated fibrin to endogenous fibrinolysis, and consequently its survival, are differentially affected by Met-α₂AP genotype. As a consequence, persons of the WW genotype would have Met-α₂AP that is less susceptible to conversion to Asn-α₂AP due to cleavage by APCE and therefore less effectively incorporated into forming fibrin, thereby making any generated fibrin more susceptible to digestion by plasmin. Experiments were conducted to demonstrate this using whole plasma to approximate native conditions as closely as possible. As indicated in the prior section, only minimal effort was made to standardize conditions under which all samples were drawn from healthy volunteers, on the basis that if indeed the WW genotype group had shortened fibrinolysis times, then odds should favor this being the case for the majority of time. Most of the perturbants known to affect fibrinolytic times—either acutely or chronically—are in play over one's lifetime, and in spite of such influences, we posited that on the average, fibrinolytic status would segregate according to Met-α₂AP genotype. Noteworthy is that in all our analyses, persons of RR genotype had the longest mean PCLT, with the RW group intermediate, and those in the WW genotype the shortest, suggesting that WW persons chronically have a more active fibrinolytic system than the RW group, and certainly greater activity than those with the RR genotype. The RR genotype contained a higher than expected percentage of persons whose fibrin never lysed, and if these were assigned PCLT values one second above the maximum measured value for any person in our study, then for men, the association of mean lysis times with RR and RW achieved significance at the p<0.05 level. Our results indicated that over one's lifetime, the W allele can serve as a “protection factor” (in contrast to the well-understood term, “risk factor”) by increasing the susceptibility of developing intravascular thrombi to removal by plasmin thereby decreasing the risk for atherosclerosis.

Further, these results demonstrated the utility in increasing Met-α₂AP/Asn-α₂AP ratios to approximate those that accelerate fibrinolysis. By decreasing the function of α₂AP-essentially the sole in vivo inhibitor of plasming to levels that carry little risk of major bleeding, as exemplified in heterozygote deficiencies of α₂AP function, and a chronic level of endogenous lytic activity sustained, then the survival and participation of intravascular fibrin-platelet thrombi in the atherosclerotic process can be reduced. In other work, plasma samples were taken from metastatic colon cancer patients who were experimentally treated with oral Val-boroPro (talabostat) which we have demonstrated is a non-specific inhibitor of APCE. Results showed that the APCE inhibitor Val-boroPro raises the percentage of Met-α₂AP in plasma indicating less conversion of Met-α₂AP to Asn-α₂AP by APCE.

Fibrin is key to stabilization of platelets as they adhere and aggregate at a site of injury of an arterial wall during the earliest stage of plaque development. Fibrin continues to be laid down as oxidized lipid and macrophages infiltrate the site of injury, and the plaque grows to gradually encroach on the diameter of the lumen with risk of rupture and acute occlusive thrombus formation. During all these stages, if fibrin contains high or maximal α₂plasmin, then the vulnerability of the fibrin to removal by the endogenous fibrinolytic system is decreased than if the fibrin contains lesser amounts of α₂AP inhibitor. With higher circulating blood levels of precursive α₂AP, (Met-α₂AP) less total α₂AP becomes crosslinked to fibrin, causing the fibrin to be more easily digested and cleared from the plaque site by the fibrinolytic enzyme, plasmin. If, however, its derivative, Asn-α₂AP dominates, then fibrin is more resistant to removal by fibrinolysis. By inhibiting APCE, then Met-α₂AP is increased in concentration in blood and any fibrin that forms is more easily removed by one's own fibrinolytic system. The presently disclosed inventive concept(s) in one embodiment therefore are directed to using the inhibitor compounds described herein to inhibit APCE to increase Met-α₂AP concentration in the blood.

FRET Peptide Substrates

The presently disclosed inventive concept(s) include, in one embodiment, fluorescence resonance energy transfer peptides (FRET-peptides) having a P—N (proline-asparagine) scissile bond (P₁-P₁′) and having an amino acid (such as (but not limited to) a gly or D-ala) in the P₂ position upstream of the P₁ proline. The FRET-peptides may comprise a quenching group, e.g., DABCYL, on one side of the P₁P₁′ bond and a fluorophore group, e.g., EDANS, on the other side of the scissile bond, or a reporter group (discussed below) on one side of the scissile bond. In certain non-limiting embodiments, the FRET peptide has up to 13 amino acid residues upstream of the P₁ proline and up to 13 residues downstream of the P₁′ asparagine residue (i.e., the entire peptide including up to 28 amino acids). The amino acid which bears the quenching group (e.g., lysine) may be one of the up to 13 amino acids upstream or downstream of the P₁-P₁′ group and the amino acid which bears the fluorophore group (e.g., glutamic acid) may be one of the up to 13 amino acids upstream or downstream of the P₁-P₁′ group. In certain non-limiting embodiments, the quenching and fluorophore groups are at the distal ends of the FRET peptide, and in particular non-limiting embodiments, at least one end of the peptide is terminated with an arginine residue (or other positively-charged amino acid), or alternatively one end may have a positively-charged amino acid and the other end may have a negatively-charged amino acid.

When the substrate has a reporter group for providing a signal, the reporter group is for example, but not limited to, at least one of 7-amido-4-methylcoumarin (AMC), 7-amino-trifluoromethylcoumarin (AFC), ethyl ester (OEt), methyl ester (OMe), 2-Naphthylamide (2NA), p-Nitroanilide (p-NA), p-Nitrophenyl ester (ONp), or Thiobenzyl ester (SBzI). When the substrate has a reporter group, a group is needed on only one side of the scissile bond.

The terms “heterocycle” or “heterocyclic” refer to ring structures, such as (but not limited to) 4, 5, 6, or 7-membered ring structures, and in particular (but not by way of limitation) to 5- to 6-membered rings, whose ring structures include one to four heteroatoms such as nitrogen, sulfur, or oxygen. Heterocyclic groups include, but are not limited to, thiophene, furan, pyran, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, and pyridazine.

The heterocyclic ring can be substituted at one or more positions with such substituents as, for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, CF₃, CN, or the like.

The term “carbocycle” or “carbocyclic”, as used herein, refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon and in certain non-limiting embodiments comprises 4, 5, 6 or 7 carbons per ring, such as (but not limited to) 5 or 6 carbons per ring.

The proline analogs and derivatives or other amino acids of the peptidomimetic compounds of the presently disclosed inventive concept(s) may exist in particular geometric or stereoisomeric forms. The presently disclosed inventive concept(s) include all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the presently disclosed inventive concept(s). Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in the presently disclosed inventive concept(s).

FIG. 1 shows an example of a FRET peptide (SEQ ID NO:1) having the native amino acid sequence surrounding the P₁-P₁′ bond of the Arg6 form of Met-α₂-AP. The rationale for including up to 13 residues on either side of the cleavage bond is to include like numbers of amino acid residues on either side of the P₁-P₁′ bond, since this level of symmetry minimizes potential steric problems as the enzyme and the substrate bind to cleave the P₁₂-N₁₃ (i.e., P₁-P₁′) bond. In this embodiment, optional arginine groups at each terminus enhance solubility of peptide derivatives when the —P—N— bond is cleaved. The G₁₁ (glycine) may be substituted with alanine or serine (such as (but not limited to) D-alanine for example). P₁₂ (i.e., P₁) is desirably (but not limited to) proline if the peptide (or peptidomimetic) is intended to be a substrate of APCE having significant cleavability. The proline may be substituted with other proline-derivatives or analogs or proline-like amino acids in peptides intended for use as inhibitors as discussed in more detail below. P₁₂—N₁₃— is the scissile bond. P₁₂, as noted, may be substituted to form an inhibitor. Fluorescent and quenching groups of the FRET peptide are each coupled to amino acids, such as E and K near the termini in this embodiment or a reporter group may be linked thereto as discussed elsewhere herein. M₁ is the N-terminal methionine residue of the native sequence of precursor α₂AP.

FIG. 2 shows a derivative peptide sequence (SEQ ID NO:2) having potential permutations of acceptable substitute amino acids at specific positions of a peptide comprising amino acids 8-18 of the peptide of FIG. 1, which can be used as a APCE/FAP substrate.

In a particular non-limiting embodiment of the cleavable substrate peptide, the quenching group and the fluorophore group is each coupled to an amino acid residue which are on either side of the scissile bond and which are desirably (but not limited to) within 1.0 to 5.0 nm of the scissile bond. In another particular non-limiting embodiment, quenching and fluorophore groups are attached to any of the residues upstream of the P₂ glycine residue, or downstream of the P₁′ (asparagine or an appropriately substituted amino acid) residue, wherein the quenching group is on one side of the P₂ or P₁′ residue, and the fluorophore group is on the other side of the P₂ or P₁′ residue, opposite the quenching group. A reporter group such as (but not limited to) at least one of 7-amino-4-methylcoumarin (AMC), 7-amino-trifluoromethylcoumarin (AFC), ethyl ester (OEt), methyl ester (OMe), 2-Naphthylamide (2NA), p-Nitroanilide (p-NA), p-Nitrophenyl ester (ONp), or Thiobenzyl ester (SBzI) may be used instead of a quenching group and a fluorophore.

Proline (or a carbocyclic or heterocyclic proline analog, derivative or substitute) at the “P₁” position is a required residue for binding to APCE and FAP. Working through a set of substitutions at various residues upstream from the P₁ proline, we found that a positively charged amino acid (e.g., arginine, lysine or histidine or others described herein) at P₇ (i.e., the sixth residue upstream of the proline) or at positions P₅ or P₆ (or an equivalent position) were particularly favorable for optimizing binding to APCE and thus the cleavage rate. Labeling discussed herein in reference to P₅, P₆, P₇ refers to the residues as increasingly numbered from the Pro residue in the scissile bond in the N-terminal direction. Pro, for example, is P₁, with the subscript number increasing in the upstream direction.

At position P₇, Arg was the optimal amino acid with a relative cleavage rate of about 5-10-fold faster than other amino acids except lys, which was about 70% of the arg rate. The arginine enhancement effect was also observed when arginine was in the P₆ or P₅ position (i.e., 4 or 5 residues upstream of the P₁-P₁′ bond), but cleavage rates diminished when arg was in positions P₈, P₄, P₃ or P₂ of the P₁-P₁′ bond. Positively charged residues, such as lys and his (or others described or contemplated herein), can be substituted for arg in the P₇, P₆ and P₅ positions, indicating the effect on cleavage rate of P₁-P₁′ is substantially positive-charge dependent (although pro, phe, tyr, trp, and some other amino acids have partial levels of activity) and other positively-charged amino acids can be substituted at this position as well.

In an alternative embodiment of the presently disclosed inventive concept(s), the FRET peptide may comprise a peptide sequence as shown in FIG. 3 (SEQ ID NO:3) wherein positions X₁-X₆ and X₈ may comprise an amino acid selected from the group of amino acids indicated below each of X₁-X₆ and X₈, with the proviso that at least one of X₁-X₃ is selected from R, H and K, or other non-protein amino acid with a positively charged side-chain (i.e., is a positively charged amino acid). Further, at least one of one, two, three or all of X₂, X₃, X₄, and X₅ may be absent. As noted above, the FRET peptide comprising SEQ ID NO:3 (or any peptide or peptidomimetric) may comprise up to and including 28 amino acids. Further, the compound may comprise a spacer in place of any or all of X₂ to X₅.

In certain non-limiting embodiments, the FRET peptide comprising SEQ ID NO:3 comprises a quenching group and a fluorophore on opposite sides of the pro-X₈ bond. SEQ ID NO:3 may further comprise a 1-10mer peptide upstream of the N-terminal amino acid in the N-terminal direction and which may comprise any of the 20 natural amino acids, and may further comprise a 1-10mer peptide downstream of the X₈-terminal amino acid in the C-terminal direction and which may comprise any of the 20 natural amino acids.

As noted above, the FRET peptide substrate may comprise the quenching group upstream of the P₁-P₁′ bond (sissile bond) and the fluorophore downstream of the P₁-P₁′ bond, or the FRET peptide may comprise the quenching group downstream and the fluorophore upstream of the P₁-P₁′ bond or may comprise a reporter group, for example downstream of the P₁-P₁′ bond. In certain non-limiting embodiments, the P₁ is proline or an effective proline analog or substitute, as described herein P₁′ (X₈) is desirably (but not limited to) asparagine or serine, and a P₂ (X₆) group upstream of P₁ is desirably (but not limited to) glycine, D-alanine, D-serine, or D-threonine.

Screening for APCE and FAP Inhibitors

In a particular embodiment, the presently disclosed inventive concept(s) include a method of screening for inhibitors of APCE (and FAP), comprising: providing a FRET peptide as contemplated herein, comprising a P₁-P₁′ bond and comprising a fluorophore (e.g., EDANS) and a quenching group (e.g., DABCYL) separated by the P₁-P₁′ bond such, or a reporter group that the peptide can be cleaved by α₂-antiplasmin cleaving enzyme, providing a quantity of α₂-antiplasmin cleaving enzyme, exposing the α₂-antiplasmin cleaving enzyme to an APCE/FAP inhibitor candidate to form a test mixture, combining the test mixture with the FRET peptide, and measuring the fluorescence emission from the test mixture to identify when the activity of α₂-antiplasmin cleaving enzyme is inhibited by the α₂-antiplasmin cleaving enzyme inhibitor candidate. Any cleavable substrate of APCE which produces an observable signal (fluorescence or other signal), such as discussed elsewhere herein, may be used in place of the FRET peptide, such as an APCE substrate having a reporter group linked thereto.

APCE/FAP Inhibitors

As described herein, various sequence variations of APCE substrates can be used to form inhibitor compounds. In particular, substitutions of the proline of the scissile bond with proline analogs have led to development of specific APCE and FAP inhibitors as described herein. The presently disclosed inventive concepts thus include APCE-inhibitory and FAP-inhibitory peptidomimetics having up to 28 amino acids or more, but desirably (but not by way of limitation) fewer, and which comprise proline analogs and derivatives for use as a P₁ proline substitute, including, but not limited to, the proline analogs and derivatives shown in Table 1 or discussed or described elsewhere herein. In certain non-limiting embodiments, the peptidomimetics (inhibitors) comprise 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 amino acids, and a spacer compound for separating certain amino acids of the compound, or compounds which may be bound or complexed thereto for extending the serum life of the peptide. Such spacers are discussed further below.

In certain non-limiting embodiments, the inhibitors of the presently disclosed inventive concept(s) possess a positively charged residue at a distance corresponding to the length of four to seven residues upstream of the proline analog (0.3 nm-2.4 nm) and can be used as a rapid, tightly binding and effective inhibitor of APCE or FAP. In addition, such inhibitors can be useful for the treatment of disorders relating to FAP, for example as described elsewhere herein.

The spacing of the positive charge in any of the P₅, P₆ or P₇ positions from the “P₁-P₁′ scissile bond” is a relevant determinant and therefore any amino acids or other spacers constructed of inert or neutral substances which fill this space to achieve the approximate length (i.e., 0.3 nm-2.4 nm) will be effective in constructing an APCE/FAP inhibitor. In a particularly favorable embodiment of the FRET peptide or APCE/FAP inhibitor, the arginine (or other positively-charged amino acid) is within from 6-21 Å (0.6 nm-2.1 nm) of the proline (or P₁ residue substitute).

The inhibitors or substrates may comprise a sequence having 2-6 amino acids in the N-terminal direction from the proline or proline substrate, including a positively-charged amino acid (such as, but not limited to, arginine, lysine, or histidine), such as (but not limited to) a glycine, D-alanine, D-serine, or D-threonine at P₂. The inhibitors may also comprise a negatively-charged or aromatic amino acid (e.g., asn, gln, asp, glu, trp, tyr, and phe) at a position downstream (C-terminal direction) from the proline or proline substitute.

In a particular non-limiting embodiment, the inhibitor or FRET peptide of the presently disclosed inventive concept(s), the compound comprises a spacer (linker or filler) group between the P₂ (glycine, D-alanine, D-serine or D-threonine) group and the positively-charged amino acid (e.g., arginine) on the N-terminal side, wherein the positively-charged amino acid e.g., arg, his, or lys or other listed herein, is desirably (but not by way of limitation) in a position equivalent to P₇, P₆ or P₅. The spacer (i.e., linker or filler) between the P₂ group and the positively-charged amino acid in the P₅, P₆ or P₇, position may for example comprise a plurality of neutral, non-charged amino acids e.g., glycine, alanine, leucine, isoleucine, valine, proline, methionine, tryptophan, tyrosine, threonine, serine, β-alanine, γ-amino butyric acid, epsilon amino caproic acid; or PEG_(n) (n=1-6), PPG_(n) (n=1-6), amino-PEG_(n)-carboxy group (n=1-6), including for example, 8-amino-3,6-dioxaoctanoic acid, 11-amino-3,6,9-trioxaundecanoic acid, and 14-amino-3, 6, 9, 12-tetraoxatetradecanoic acid, and amino-PPG_(n)-carboxy oligomers (e.g., n=1-6). These spacers may be homogenous (e.g., all glycine, alanine, etc., or other single amino acid) or heterogeneous (e.g., more than one type of amino acid, ethylene glycol/propylene glycol, or a hybrid amino acid/amino-PEG_(n)-carboxy or amino-PPG_(n)-carboxy where n=1-6), and is desirably (but not by way of limitation) 3.0-21 Å (0.3 nm-2.1 nm) (or 1 to 7 amino acids) in length. The spacer may be comprised of neutral monomers comprising ethylene glycol for example, or other similar monomer units (e.g., propylene glycol), which together have a length of 3.0-21 Å (0.3 nm-2.1 nm) such that the spacer places the arginine (or other positively charged amino acid) within about 5-25 Å (0.5 nm-2.5 nm) of the proline or proline substitute or analog or derivative at the P₁ position.

Therefore the presence of a positively-charged amino acid within the distance as defined herein is an aspect of the presently disclosed inventive concept(s) that contributes significantly to the specificity of binding to the APCE/FAP sequence. Use of D-alanine or D-serine at the P₂ position has been found to particularly enhance the specificity of the inhibitor for APCE/FAP.

In one embodiment, the inhibitors of the presently disclosed inventive concept(s) comprise compounds having Formula I as shown below:

B-Xaa₁-Sp-Xaa₂-Cyc  (Formula I).

In this embodiment Xaa₁ is a positively-charged amino acid, including but not limited to, α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine, β-homoarginine, homoarginine, lysine, homolysine, β-homolysine, or histidine.

B is a blocking (protecting) group. Examples of such protecting groups include, but are not limited to, aminobenzoyl (Abz), acetyl (Ac), benzoyl (Bz), carbobenzoxy, benzyloxycarbonyl (Z), t-Butyloxycarbonyl (Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate (Pyr), Phenylalanine, peptides comprising any combination of 1-3 natural amino acids, and Succinyl (Suc). In other embodiments, B may be absent such that the compound comprises the Formula Ia: Xaa₁-Sp-Xaa₂-Cyc. Where present, the blocking group B desirably (but not by way of limitation) has a molecular weight <400 Dal., such as (but not limited to) a molecular weight <300 Dal.

Sp is a spacer molecule, which has a length of 0.3 nm to 2.5 nm. Examples of such spacer molecules include, but are not limited to, γ-aminobutyric acid, ε-aminocaproic acid, 8-amino-3,6-dioxaoctanoic acid, 11-amino-3,6,9-trioxaundecanoic acid, 14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid; 5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid; 8-aminooctanoic acid; 3-(aminooxy)acetic acid, β-alanine, gly, ala, thr, trp, tyr, met, leu, ile, val, ser, proline, a PEG_(n); PPG_(n), an aminocarboxy PEG_(n) or PPG_(n), or a combination of any of the above wherein Sp has a length of 0.3 nm to 2.5 nm, and wherein n=1-6.

Xaa₂ is glycine, D-alanine, D-serine, or D-threonine.

Cyc is a carbocyclic or heterocyclic ring. The carbocyclic ring may comprise 4, 5, 6, or 7 carbon atoms, for example. The heterocyclic ring may comprise 4, 5, 6, or 7 atoms, for example wherein at least one atom is a heteroatom such as nitrogen or other atom as discussed elsewhere herein. The compound may further comprise one or more amino acids extending upstream from the Cyc group, including, but not limited to aspartic acid, glutamic acid, glutamine, aspargine, serine, threonine, histidine, tyrosine, alanine, phenylalanine, glycine, valine, leucine, isoleucine, methionine, tyrosine, tryptophan, or any negatively-charged or aromatic amino acid. Examples of Cyc include, but are not limited to, those shown in Table 1 and desirably (but not by way of limitation) comprise boronyl prolines (L, D, or D/L), carbonitrile prolines or nitrile pyrrolidines.

Examples of various APCE/FAP inhibitor compounds of the presently disclosed inventive concept(s) having the structure of Formula I are shown in Table 2.

In a particular non-limiting embodiment, the inhibitor compounds of the presently disclosed inventive concept(s) are non-immunogenic (i.e., induce no antibody response) and have zero cell membrane permeability, and have a solubility in water of at least 5 mg/ml.

The inhibitors described herein may comprise isostere bonds. For example, alternative embodiments of an inhibitor of the presently disclosed inventive concept(s) having the structure of Formula I are shown in FIG. 4. FIG. 4A shows a compound comprising acetyl-arginyl-amino-PEG₂-carboxy-D-alanyl-L-boroproline. FIG. 4B shows a derivative thereof wherein the carbonyl of the carboxyl group of the arginine moiety has been reduced to a methylene group to form a reduced isostere bond between the residual arginine group and the amino-PEG₂-carboxy spacer group. Any of the inhibitor compounds of the presently disclosed inventive concept(s) may comprise such a reduced isostere bond, or may be formed with the regular peptide bond, between the arginine (or other positively-charged amino acid) and the spacer group, i.e., between Xaa₁ and Sp. The reduced isostere bond is effective in further reducing peptidase activity upon the compound. Other examples of proline analogs which can be used herein are shown in the structures of FIG. 5.

The compound may further comprise, with, or in place of B, an N-terminal oligopeptide having 1 to 10 amino acids extending in an N-terminal direction from Xaa₁, and/or a C-terminal oligopeptide having 1-10 amino acids extending in a C-terminal direction from Cyc, wherein the N-terminal oligopeptide and C-terminal oligopeptide may comprise one or more of the 20 naturally-occurring amino acids in any combination.

In a particular non-limiting embodiment of the inhibitor compound, D-Ala replaces Gly, because we observed in a surprising result that this unnatural amino acid significantly amplified its selectivity for FAP or APCE versus inhibition of DPPIV. For example, as shown in Table 4, an inhibitor of the presently disclosed inventive concept(s) comprising D-ala-L-boroPro had an APCE Ki=5.7 nM and DPPIV Ki=6130 nM, while an inhibitor comprising Gly-boroPro had an APCE Ki=1.8 nM and DPPIV Ki=440 nM. Unlike FAP, DPPIV is expressed by normal tissues and is involved in normal physiologic reactions, therefore a high Ki (low affinity) for DPPIV is greatly preferred. The D-ala-containing inhibitors desirably (but not by way of limitation) inhibit APCE with a Ki in the low nm range (e.g., such as (but not limited to)<20 nM, or <15 nM and more in particular (but not by way of limitation)<10 nM) and do not significantly inhibit DPPIV (e.g., >5,000 nM), unless used at unacceptable and unusually high concentrations. In a particular non-limiting version of the presently disclosed inventive concept(s), the inhibitor compounds are highly selective for APCE and FAP versus DPPIV. For example the ratio of Ki (DPPIV): Ki (APCE/FAP) is desirably (but not by way of limitation) >200, such as (but not limited to) >500, or >600, or >700, or >800, or >900, or in particular (but not by way of limitation) >1,000. In certain non-limiting embodiments, the Ki (DPPIV) is >200 nM, such as (but not limited to) >500 nM, >1,000 nM, >2,500 nM, or >4,000 nM, and in particular (but not by way of limitation) >5,000 nM or >6,000 nM. In a particular non-limiting embodiment, the Ki (DPPIV) is >7,500 nM, such as (but not limited to) >10,000 nM.

Hence, the inhibitors exhibit very good to excellent selectivity and are highly water soluble, and given this length, and the lack of exposed amino-terminal amino group should not be involved in cyclization with resultant loss of activity. In particular non-limiting embodiments, a chemotherapeutic agent, such as described below, can be linked to the inhibitor molecule, directly via an exposed amino or carboxy group or via a linking group.

In an alternative embodiment, the presently disclosed inventive concept(s) include a compound which comprises the “stalk” portion of the compound of Formula I, i.e., B-Xaa₁-Sp-Xaa₂ (Formula Ib) used as a targeting agent or delivery agent, to deliver a “warhead” (i.e., Cyc, or other compound) which is desired to be delivered to FAP or APCE. The presently disclosed inventive concept(s) are thus directed to compounds comprising or otherwise based on this “stalk” as a component, and use of these compounds in any therapeutic, diagnostic, or assay method described, contemplated, or enabled herein.

In certain non-limiting embodiments, the compound is disposed in a pharmaceutically-acceptable carrier as described elsewhere herein.

In certain non-limiting embodiments, the molecular weight of the inhibitor compound is <1000 Dal., such as (but not limited to)<800 Dal., or <600 Dal.

In another embodiment, the presently disclosed inventive concept(s) comprise APCE substrates comprising Formula II as shown below:

Xaa₁-Sp-Xaa₂-Pro-Xaa₃  (Formula II).

As substrates of APCE, these do not inhibit APCE or FAP.

In this embodiment Xaa₁ is a positively-charged amino acid such as, but not limited to, α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine, β-homoarginine, homoarginine, lysine, homolysine, β-homolysine, or histidine.

Sp is a spacer molecule comprising one or more of γ-aminobutyric acid, ε-aminocaproic acid, 8-amino-3,6-dioxaoctanoic acid, 11-amino-3,6,9-trioxaundecanoic acid, 14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid; 5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid; 8-aminooctanoic acid; 3-(aminooxy)acetic acid, β-alanine, ala, thr, trp, tyr, met, leu, ile, val, ser, proline, PEG_(n) (n=1-6), PPG_(n) (n=1-6), aminocarboxy PEG_(n) (n=1-6), aminocarboxy PPG_(n) (n=1-6), or a combination of any of the above wherein Sp has a length of 0.3 nm to 2.5 nm.

Xaa₂ is a glycine, D-alanine, D-serine, or D-threonine. Pro is proline, or a proline analog which can form a P₁-P₁′ bond which is cleavable by APCE. Xaa₃ is asparagine or another amino acid such as, but not limited to serine, histidine, tyrosine, alanine, phenylalanine, and glutamine or any other amino acid which can form a bond cleavable by APCE, particularly the natural amino acids. The substrate may further comprise peptides (n=1-10) extending from the N-terminal amino acid and/or the C-terminal amino acid.

EXPERIMENTAL

The following describes various experimental procedures used to synthesize examples of inhibitors for further examination herein.

Materials.

Gly-Pro-7-amino-4-methylcoumarin (Gly-Pro-AMC) and benzyloxycarbonyl (Z)-Gly-Pro-AMC were from Sigma and Bachem, respectively. Fmoc-pipecolinic acid and Fmoc-(3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (“tic”) were from Advanced Chemtech; pyrrolidine and piperidine were from Aldrich. MEPLGRQLTSGP-AMC (SEQ ID NO:4), MEPLGWQLTSGP-AMC (SEQ ID NO:5), peptide substrate analog inhibitors, and peptide libraries were synthesized in the Molecular Biology-Proteomics Facility, University of Oklahoma Health Sciences Center. Met-α2AP(R6) and APCE were purified as previously described from fresh frozen human plasma purchased from the Sylvan Goldman Blood Institute, Oklahoma City Okla. (24).

Synthesis of Inhibitors.

A series of 11 inhibitors were synthesized for analysis. Inhibitors 1-4 and 11 listed in Table 3 were prepared according to the Fmoc synthesis procedure utilizing the HBTU/HOBT activation method (the activation reaction consisted of 3.3 eq. of HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), 3.3 eq. of HOBT (1-hydroxybenzotriazole), 6.6 eq. diisopropylethylamine, 3.3 eq. of protected amino acid and 1.0 eq. of amino acid or peptide), linked to the synthesis solid-support. All reactions were carried out in N-methyl pyrrolidone. The syntheses were done by solid-phase methods employing 4-alkylbenzyloxy alcohol resins for inhibitors 1-4 and Rink 4-methylbenzhydrylamine resin for inhibitor 11. Inhibitors 5-10 were partially synthesized, including all but the C-terminal structure, utilizing the above methods on glycine-2-chlorotrityl resins on all except inhibitor 7, where 8-amino-3, 6-dioxaoctanoic acid-2-chlorotrityl resin was used. For inhibitors 5-10, chemically protected peptides were released from the synthesis resin by treatment with 3% trifluoroacetic acid in dichloromethane. The protected peptides were then purified by reversed-phase HPLC. Inhibitors 5-7 precursors were prepared by this method and then each protected peptide's free carboxyl-terminus was linked to a five-fold excess of pyrrolidine (inhibitors 5-7), or fluoropyrrolidine (inhibitors 8 & 9), or piperidine (inhibitor 10) by in-solution reaction utilizing the HATU/DIEA linkage reaction in dimethylformamide. HATU/DIEA linkage reaction mixture contained 1.2 equivalents of HATU (2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), 2.4 eq. of diisopropylethylamine and 1.0 eq. of protected peptide. The reaction products were chemically deprotected by treatment with 90% trifluoroacetic acid, 5% triisopropyl silane and 5% water and then dried. Finally, each inhibitor was purified by reversed-phase HPLC and analyzed by electrospray mass spectrometry.

Enzyme Assays.

APCE or DDPIV was incubated in 25 mM sodium phosphate buffer, pH 7.5, containing 1.0 mM EDTA and 4% methanol in a total volume of 200 μl for 20 min at 22° C., using fluorescent substrates MEPLGRQLTSGP-AMC (SEQ ID NO:4) (12.5-100 μM); MEPLGWQLTSGP-AMC (SEQ ID NO:5) (12.5-100 μM); Z-Gly-Pro-AMC (25-200 μM); or GP-AMC (62.5-1000 μM). To avoid solubility of Z-Gly-Pro-AMC, the same assay buffer contained 4% methanol. Fluorescence was monitored with time at excitation and emission wavelengths of 360 and 460 nm using a black-sided, 96-well plate in a BIO-TEK FL600 fluorescence plate reader. For standard curves, dilutions of AMC (7-amino-4-methylcoumarin) were prepared in the same assay buffer and corresponding fluorescence was measured. The substrates in five different concentrations were mixed with four different concentrations of inhibitors around the expected Ki values; the enzyme was added and enzymatically released AMC fluorescence was recorded. Competitive inhibition was established by Lineweaver-Burk plot. Therefore, enzyme kinetic parameters were computed by fitting data to the following equation, employing the program PRISM, GraphPad:

$v = \frac{V_{\max}\lbrack S\rbrack}{{K_{m}\left( {1 + \frac{\lbrack I\rbrack}{K_{i}}} \right)} + \lbrack S\rbrack}$

APCE residue preferences in P4-P4′ substrate peptides. To determine substrate specificity in P4-P4′, peptides were derived from the contiguous sequence of four amino acids on either side of the APCE Pro¹²-Asn¹³ cleavage site in Met-α₂AP. Eight peptide position libraries were prepared; each library consisted of different peptides with each having a single amino acid position substituted utilizing all native amino acids except Cys. Within each library, the 19 peptides were distributed into three sub-libraries with six or seven peptides in each. The peptides in a sub-library were selected so that the molecular weight differences among them were maximized. Each of the three sub-libraries contained a common specific reference peptide. In total, there were 152 peptides with each differing from the others by a single amino acid in the 24 sub-libraries representing the eight position libraries. Each sub-library was incubated with APCE and relative cleavage rates for each peptide in the mixture were compared.

Reaction mixtures contained peptide concentrations of 67 μM and APCE at 0.5-2 μg. Amounts of cleaved peptides were determined at 0.25, 0.50, 0.45, 1.0, 1.5, 3.0, 4.0, and 24 hr. To buttress conclusions about P4-P4′ substrate specificity from the LC/MS data, reactions were carried out below 15% substrate consumption to assure cleavage rates remained within a linear range. Cleavage rates of peptide substrates in the P1-P4 sub-libraries by APCE were determined by liquid chromatography/mass spectrometry (LC/MS) analysis. Peptide libraries representing residue numbers six through 17 (FRQLTSGP-NQEQV—SEQ ID NO:6) of Met-α₂AP(R6) sequence were incubated with APCE; each bold and underlined letter represents the varied amino acid. FRQL sequence was added to make the N-terminal product larger in molecular weight than the C-terminal product. The N-terminal Phe, not native to Met-α₂AP, was added to enhance binding to the reversed-phase HPLC column.

To determine P1′-P4′ substrate specificity, peptide cleavage rates were analyzed by MALDI-TOF MS. Peptide libraries representing residue numbers nine through 18 (ATSGP-NQEQVSFR—SEQ ID NO:7) of Met-α₂AP sequence, with each bold letter representing the varied amino acid, were also incubated with APCE. N-terminal Ala and C-terminal Phe and Arg were added to improve MALDI-TOF MS analysis.

LC/MS Analysis of Met-α₂AP Hydrolysis by APCE.

Met-α₂AP(R6) (13 μg) was incubated with APCE (0.2 μg) and various concentrations of inhibitor in 100 μl of 25 mM sodium phosphate-1.0 mM EDTA buffer, pH 7.5. After incubating for 6 hr at 37° C., an internal standard peptide (FRQLTSG-tic-NQEQV—SEQ ID NO:8, 0.11 μg) was dissolved in the reaction mixture and cold acetonitrile (4× sample volume) was added to precipitate proteins (“tic” refers to 1, 2, 3, 4 tetrahydro isoquinoline-3-carboxylic acid). The sample was incubated at −80° C. for 60 min and centrifuged for 10 min at 16,000×g at 4° C. to remove precipitated proteins. The supernatant, which contained the N-terminal 12-residue peptide of Met-α₂AP(R6), was removed, dried by vacuum centrifugation and dissolved in 5% acetic acid.

Hydrolysis products contained in the supernatant were analyzed by LC/MS, using a Paradigm MS4B HPLC system (Michrom Bioresources) equipped with a reversed-phase column (0.5 mm×150 mm Magic MS C18 column with 5 micron particles and 20 nm pores) operated at 20 μl/min. The column was equilibrated with 2% acetonitrile/water containing 0.09% formic acid and 0.01% TFA. Upon sample injection, the solvent composition was increased to 10% acetonitrile and a linear gradient was applied to 50% acetonitrile over 40 min. Peptides were detected at 215 nm wavelength. The HPLC effluent was connected to an HCTultra ion trap mass spectrometer, Bruker Daltonics, equipped with an electrospray ion source operated in the positive ion mode. Data were collected over an M/z range of 300 to 1800 amu. Both the internal standard peptide and the peptide product of digestion were located by extracted ion current analysis of data for each peptide over a 1.5 amu window for singly and doubly charged forms of each peptide, based on the peptide's predicted monoisotopic molecular mass. Quantification was performed by summing all detected ions from the total ion chromatogram for all observed charge forms and all isotopic forms detected above background for each peptide ion over a two min window beginning when peptide ions were first observed.

Immunoblot analysis of Met-α₂AP cleavage by APCE. Reaction mixtures made to contain APCE, Met-α₂AP(R6), and one of the inhibitors from Table 2 were prepared as described above, incubated for 6 hr, subjected to SDS-PAGE, transferred to a nitrocellulose membrane, and Met-α₂AP(R6) was then detected by immunostaining with an antibody specific for its N-terminal sequence and non-reactive with Asn-α₂AP (1).

Shown in Table 4 is a set of inhibitors of the presently disclosed inventive concept(s) wherein the amino acid in the “P₂” position is either glycine, D-alanine, or aspartic acid, having an N-terminal acetyl group as a protecting group and boronyl proline in the “P₁” (Cyc) position as the proline analog. Affinity constants for binding to APCE and DPPIV are indicated. Indicated therein are results showing that inhibitors comprising D-alanine in the P₂ position adjacent the proline analog have substantially reduced binding affinity for DPPIV (e.g., see “Ac-Arg-peg-D-Ala-L—boroPro”).

In one embodiment, as noted elsewhere herein, the presently disclosed inventive concept(s) include a method of altering a plasma α₂-antiplasmin ratio in a subject having a pretreatment level of plasma Met-α₂-antiplasmin and a pretreatment level of plasma Asn-α₂-antiplasmin. In particular, the method comprises treating the subject with an inhibitor of APCE as described herein wherein the inhibitor specifically inhibits cleavage of the Pro-Asn cleavage site of Met-α₂-antiplasmin by antiplasmin cleaving enzyme, wherein after treatment the subject has a posttreatment level of plasma Met-α₂-antiplasmin which is at least 5% greater than the pretreatment level of plasma Met-α₂-antiplasmin, and has a posttreatment level of plasma Asn-α₂-antiplasmin which is at least 5% less than the pretreatment level of Asn-α₂-antiplasmin, thereby altering the plasma α₂-antiplasmin ratio in the subject. In the method, the alteration of the α₂-antiplasmin ratio in the subject preferably enhances fibrinolysis in the subject. In particular, the method is a treatment for inhibiting or treating atherosclerosis, arterial thromboses, venous thromboses, stroke, or pulmonary embolism.

In one embodiment of the method, the inhibitor is provided such that the posttreatment level of plasma Met-α₂-antiplasmin is at least 10% greater than the pretreatment level of plasma Met-α₂-antiplasmin and the posttreatment level of plasma Asn-α₂-antiplasmin is at least 10% less than the pretreatment level of plasma Asn-α₂-antiplasmin. In another embodiment, the inhibitor is provided such that the posttreatment level of plasma Met-α₂-antiplasmin is at least 15% greater than the pretreatment level of plasma Met-α₂-antiplasmin and the posttreatment level of plasma Asn-α₂-antiplasmin is at least 15% less than the pretreatment level of plasma Asn-α₂-antiplasmin. In another embodiment, the inhibitor is provided such that the posttreatment level of plasma Met-α₂-antiplasmin is at least 20% greater than the pretreatment level of plasma Met-α₂-antiplasmin and the posttreatment level of plasma Asn-α₂-antiplasmin is at least 20% less than the pretreatment level of plasma Asn-α₂-antiplasmin. In another embodiment of the method, the inhibitor is provided such that the posttreatment level of plasma Met-α₂-antiplasmin is at least 25% greater (and may be, for example, any percentage greater) than the pretreatment level of plasma Met-α₂-antiplasmin and the posttreatment level of plasma Asn-α₂-antiplasmin is at least 25% less (and may be, for example, any percentage less) than the pretreatment level of plasma Asn-α₂-antiplasmin.

The presently disclosed inventive concept(s) include methods of treating or inhibiting atherosclerosis, arterial thromboses, venous thromboses, stroke, or pulmonary embolism in a subject having a pretreatment level of plasma Met-α₂-antiplasmin and a pretreatment level of plasma Asn-α₂-antiplasmin by altering the α₂-antiplasmin level in the subject. The methods comprise treating the subject with an inhibitor of APCE as described herein wherein the inhibitor specifically inhibits cleavage of the Pro-Asn cleavage site of Met-α₂-antiplasmin by antiplasmin cleaving enzyme, wherein after treatment the subject has a posttreatment level of plasma Met-α₂-antiplasmin which is at least 5%, 10%, 15%, 20%, or 25% greater (or any desired percentage greater) than the pretreatment level of plasma Met-α₂-antiplasmin, and has a posttreatment level of plasma Asn-α₂-antiplasmin which is at least 5%, 10%, 15%, 20%, or 25% less (or any percentage less) respectively, than the pretreatment level of Asn-α₂-antiplasmin, thereby altering the plasma α₂-antiplasmin ratio in the subject. In certain non-limiting embodiments, the alteration of α₂-antiplasmin ratio in the subject occurs by enhancement of fibrinolysis in the subject.

The presently disclosed inventive concept(s) further include APCE/FAP inhibitor compounds described herein which are conjugated to carrier compounds which are able to pass through the cell membrane, including, but not limited to, protein transduction domains (PTDs). PTDs are positively charged peptides or peptide-like molecules that permeate cell membrane lipid bilayers. Typically PTDs contain several arginine residues and can be used to deliver other agents, such as peptides, proteins, oligonucleotides or small molecules through a cell membrane and into the cytosol. One PTD is a highly efficient molecular transporter formed by synthesizing an oligomer of arginines alternating with EACAs. PTDs are well-known in the art. Examples of PTDs which may be used herein are shown, for example, in U.S. Pat. Nos. 7,166,692; 7,217,539; 7,053,200; 6,835,810; 6,645,501; and Published U.S. Patent Applications 2002/0009491; 2003/0032593; 2003/0162719; 2006/0159719; 2006/0293234; and 2007/0105775, each of which is expressly incorporated herein in its entirety by reference.

As noted elsewhere herein, the inhibitors described herein can be used in vitro and in vivo in human plasma to inhibit the activity of APCE, thereby slowing or preventing the cleavage of precursive α₂-antiplasmin to its derivative form, which is incorporated more efficiently into fibrin and consequently, enhances inhibition of fibrin digestion by plasmin. For example, in experiments performed in our laboratory in which human plasma was used, if α₂-antiplasmin were completely absent when the plasma was clotted by thrombin and calcium, under our experimental conditions, the fibin clot lysed by ˜12 min, whereas if precursive α₂-antiplasmin (contains methionine amino-terminus sufficient), the APCE within the plasma cleaved the 12-residue amino-terminal peptide from precursive α₂-antiplasmin to generate derivative α₂-antiplasmin (asparagine amino-terminus), which when incorporated into the fibrin clot, prolonged lysis to ˜40 min. Utilizing a dose range of our inhibitors of APCE showed the following: 50 μM inhibitor: lysis time 24 min; 5 μM inhibitor: lysis time 28 min; 0.5 μM inhibitor: lysis time 34 min. Hence, these results confirm the ability to specifically inhibit APCE in plasma assays where it is desirable to minimize the generation of the more effective derivative from its precursive form in plasma. The inhibitor would allow the instantaneous inhibition of APCE so that the more reactive, derivative of α-antiplasmin would not be generated and slow the lysis of a fibrin thrombus. Hence, the time to lysis of a generated fibrin clot would reflect the actual conditions in plasma from the moment of collection from the person to the lysis endpoint of the fibrin thrombus made from the person's plasma.

Similarly, based on our results showing that the inhibitors likewise inhibit FAP with high sensitivity and specificity, the inhibitors can be used to selectively inhibit the proteolytic activity of FAP on cell surfaces of fibroblasts and cancer cells towards collagen within the extracellular matrix, and without impacting other prolyl-specific proteinases (e.g., DPPIV) for which it has no specificity thus enabling analysis of various characteristics of the sample with other prolyl-specific proteinases present while FAP is inhibited. In certain instances where other prolyl-specific proteinases are solely contained within cellular cytoplasm, the high aqueous solubility of certain disclosed inhibitors (>500 μg/ml) indicates they will not permeabilize the universal highly lipophilic, hydrophobic nature of cell membranes.

Cell Surface FAP Activity of Fibroblasts.

FIG. 6, for example, illustrates that FAP proteolytic activity expressed on the surface of living fibroblast cells can readily be inhibited by the inhibitor Ac-Arg-peg-D-Ala-boroPro (a.k.a. M83). We measured FAP activity by use of a synthetic substrate, Ac-Arg-peg-Gly-Pro-amidomethyl coumarin, which produces fluorescence upon cleavage of the bond between proline and the amidomethylcoumarin by FAP. In these experiments we made a treatment and then measured any fluorescence generated over several hours. The figure compares three treatments:

-   -   (1) “Control”: This curve represents addition of the substrate         to live cells bathed in culture media with no other treatment.         The synthetic substrate cleavage is observed as reflected by         measurement of the fluorescence generated that is expressed as         APCE Units. This represents active FAP proteolytic activity on         fibroblast cells.     -   (2) “M83 10 uM”: This curve illustrates that when the inhibitor         is added to the live cells simultaneously with the addition of         the substrate, no substrate hydrolysis occurs. This indicates         that the inhibitor blocks activity of FAP on the cell surface         immediately and completely, since no fluorescence is produced         (the curve does not change over 5 hours).     -   (3) “M83 10 uM added at 2 hrs”. This curve demonstrates that if         fibroblast cells are allowed to incubate with the substrate for         a period of time (2 hrs in this case), the synthetic substrate         is cleaved similarly to the “Control” plot. At the end of 2         hours of incubation, we added the inhibitor (at a final         concentration of 10 micromolar) and the cleavage of the         substrate was immediately arrested as shown when the curve         changed slope at 2 hours to a flat line after inhibitor         addition, indicating that no new fluorescence was generated over         a period of three hours after inhibitor addition. Thus the FAP         activity was immediately and completely arrested by addition of         our inhibitor.

Cell Surface FAP Activity of Breast Cancer Cells.

In FIG. 7, the experiment was performed in exactly the same way as for FIG. 6, except live breast cancer cells were used. These results demonstrate that cultured breast cancer cells also have FAP activity on their cell surface, as demonstrated by the curve rising with time upon addition of substrate in a manner similar to the fibroblasts of FIG. 6. The curve with the inhibitor M83 is flat and does not rise with time, indicating that no fluorescence is being produced and thus FAP activity has been completely inhibited by the addition of the inhibitor.

Utility

Further to, and in addition to the utilities already described herein, as noted above, a subject is treated with an inhibitor of the presently disclosed inventive concept(s) in a manner and in an amount so as to inhibit proliferation of a primary tumor, or to inhibit metastatic spread or growth while minimizing the potential for systemic toxicity. In certain embodiments, the abnormal mammalian cell proliferation is manifested as a tumor. Some conditions intended to be treated by the present methods include benign (i.e., non-cancerous), pre-malignant and malignant (i.e., cancerous) tumors. In some embodiments, the condition characterized by abnormal mammalian cell proliferation is further characterized by the presence of reactive stromal fibroblasts.

In other embodiments, the abnormal mammalian cell proliferation treated in the methods described and claimed herein is a carcinoma, a sarcoma, or a melanoma or others described elsewhere herein. More particularly, the condition may be, but is not limited to, a breast cancer, colorectal cancer, ovarian cancer, prostate cancer, pancreatic cancer, kidney cancer, lung cancer, melanoma, or fibrosarcoma, or bone and connective tissue sarcomas, including, but not limited to, osteosarcoma and fibrosarcoma. The abnormal mammalian cell proliferation may be in epithelial cells, meaning that it is epithelial cells which are abnormally proliferating. Some conditions characterized by abnormal mammalian epithelial cell proliferation include adenomas of epithelial tissues such as the breast, colon and prostate, as well as malignant tumors. According to other embodiments of the presently disclosed inventive concept(s), a method is provided for treating a subject having a metastasis of epithelial origin.

According to some embodiments of the presently disclosed inventive concept(s), the agent is administered locally. In some embodiments, the agent is targeted to a tumor. This can be achieved by the particular mode of administration. For example, certain more easily accessible tumors such as breast or prostate tumors may be targeted by direct needle injection to the site of the lesion. Lung tumors may be targeted by the use of inhalation as a route of administration.

In some embodiments, the agents may be administered in a systemic manner, via administration routes such as, but not limited to, oral, intravenous, intramuscular and intraperitoneal administration. Systemic administration routes may be desired in certain non-limiting embodiments, for example, if the subject has metastatic lesions. In other embodiments, the agent is administered in a sustained release formulation.

In administering the present compounds to subjects, dosing amounts, dosing schedules, routes of administration and the like may be selected so as to affect the other known activities of these compounds. For example, amounts, dosing schedules and routes of administration can be selected as described herein, whereby therapeutically effective levels for inhibiting proliferation are provided, yet are provided at levels which do not affect other proteins (e.g., enzymes necessary for healthy function such as DPPIV) in the subject.

In some embodiments of the presently disclosed inventive concept(s), a method is provided in which the inhibitor is administered in combination with surgery (before, during, or after) to remove an abnormal proliferative cell mass.

In another aspect, the presently disclosed inventive concept(s) include a method for inhibiting angiogenesis in a subject having a condition characterized by abnormal mammalian cell proliferation comprising administering to a subject in need of such treatment, an agent in an amount effective to inhibit angiogenesis in an abnormal proliferative cell mass, wherein the agent is an inhibitor as described herein.

In one embodiment, the inhibitor is provided along with at least one other anti-cancer compound (i.e., an anti-cancer compound other than an agent of Formula I, or as otherwise contemplated herein), and a pharmaceutically acceptable carrier. In another aspect, a pharmaceutical preparation is provided which comprises an agent of Formula I, at least one other anti-angiogenic compound (i.e., an anti-angiogenic compound other than an agent of Formula I, or as otherwise contemplated herein), and a pharmaceutically acceptable carrier.

In other embodiments, anti-cancer cocktails containing an inhibitor compound of the presently disclosed inventive concept(s) and other anti-proliferative compounds and/or other anti-angiogenic compounds as described herein are also provided. In still other embodiments, the agents of Formula I are used in the preparation of a medicament for treating subjects having conditions characterized by abnormal mammalian cell proliferation.

In still other embodiments, the agent may be targeted to a cell mass (e.g., a tumor) through the use of a targeting compound specific for a particular tissue or tumor type. In some embodiments, the inhibitors may be targeted to primary or in some instances, secondary (i.e., metastatic) lesions through the use of targeting compounds which preferentially recognize a cell surface marker.

As described herein, the inhibitors and substrates of the presently disclosed inventive concept(s) comprise peptides or peptidomimetics which may include non-amino acid residues such as saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. In particular, it is possible to substitute non-naturally occurring amino acids as described herein for the “P₁” proline residue. In one embodiment, the P₁ group is an analog of proline in which the carboxylate group (COOH) is replaced with a boronyl group (BOH₂). Alternative compounds of the presently disclosed inventive concept(s) have an analogous structure in which the boronyl group is replaced by, for example, a nitrile, a carbonitrile, carboxynitrile, a phosphonate or a fluoroalkylketone, alphaketos, N-peptiolyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isoesteres, peptidyl (alpha-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides, or other structures for example as shown in Table 1.

As noted herein, the presently disclosed inventive concept(s) include methods for treating a subject having a condition characterized by an abnormal cell proliferation. As used herein, subject is intended to refer to a mammal including, but not limited to, humans, apes, other nonhuman primates, dogs, cats, sheep, llamas, goats, horses, cows, pigs, and rodents. An abnormal mammalian cell proliferation disorder or condition, as used herein, refers to a localized region of cells (e.g., a tumor) which exhibit an abnormal (e.g., increased) rate of division as compared to their normal tissue counterparts.

In one aspect, as noted, the presently disclosed inventive concept(s) include methods for treating a subject having a condition characterized by an abnormal epithelial cell proliferation. Epithelial cells are cells occurring in one or more layers which cover the entire surface of the body and which line most of the hollow structures of the body, excluding the blood vessels, lymph vessels, and the heart interior which are lined with endothelium, and the chest and abdominal cavities which are lined with mesothelium. Examples of epithelial cells contemplated herein include, but are not limited to, cells of the anterius corneae, anterior epithelium of cornea, Barrett's epithelium, capsular epithelium, ciliated epithelium, columnar epithelium, corneal epithelium, cubical epithelium, cuboidal epithelium, epithelium eductus semicircularis, enamel epithelium, false epithelium, germinal epithelium, gingival epithelium, glandular epithelium, glomerular epithelium, laminated epithelium, epithelium of lens, epithelium lentis, mesenchymal epithelium, olfactory epithelium, pavement epithelium, pigmentary epithelium, pigmented epithelium, protective epithelium, pseudostratified epithelium, pyramidal epithelium, respiratory epithelium, rod epithelium, seminiferous epithelium, sense epithelium, sensory epithelium, simple epithelium, squamous epithelium, stratified epithelium, subcapsular epithelium, sulcular epithelium, tessellated epithelium, and transitional epithelium.

One category of conditions characterized by abnormal epithelial cell proliferation is proliferative dermatologic disorders. These include, but are not limited to, conditions such as keloids, seborrheic keratosis, papilloma virus infection (e.g. producing verruca vulbaris, verruca plantaris, verruca plana, condylomata, etc.) and eczema.

An epithelial precancerous lesion is a skin lesion which has a propensity to develop into a cancerous condition. Epithelial precancerous skin lesions also arise from other proliferative skin disorders such as hemangiomas, keloids, eczema and papilloma virus infections producing verruca vulbaris, verruca plantaris and verruca planar. The symptoms of the epithelial precancerous lesions include skin-colored or red-brown macule or papule with dry adherent scales. Actinic keratosis is the most common epithelial precancerous lesion among fair skinned individuals. It is usually present as lesions on the skin which may or may not be visually detectable. The size and shape of the lesions varies. This is a photosensitive disorder and may be aggravated by exposure to sunlight. Bowenoid actinic keratosis is another form of an epithelial precancerous lesion. In some cases, the lesions may develop into an invasive form of squamous cell carcinoma and may pose a significant threat of metastasis. Other types of epithelial precancerous lesions include, but are not limited to, hypertrophic actinic keratosis, arsenical keratosis, hydrocarbon keratosis, thermal keratosis, radiation keratosis, viral keratosis, Bowen's disease, erythroplaquia of queyrat, oral erythroplaquia, leukoplakia, and intraepidermal epithelialoma.

Another category of conditions characterized by abnormal epithelial cell proliferation is tumors of epithelial origin. Epithelial tumors are known to those of ordinary skill in the art and include, but are not limited to, benign and premalignant epithelial tumors, such as breast fibroadenoma and colon adenoma, and malignant epithelial tumors. Malignant epithelial tumors include primary tumors, also referred to as carcinomas, and secondary tumors, also referred to as metastases of epithelial origin. Carcinomas intended for treatment with the methods of the presently disclosed inventive concept(s) include, but are not limited to, acinar carcinoma, acinous carcinoma, alveolar adenocarcinoma (also called adenocystic carcinoma, adenomyoepithelioma, cribriform carcinoma and cylindroma), carcinoma adenomatosum, adenocarcinoma, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma (also called bronchiolar carcinoma, alveolar cell tumor and pulmonary adenomatosis), basal cell carcinoma, carcinoma basocellulare (also called basaloma, or basiloma, and hair matrix carcinoma), basaloid carcinoma, basosquamous cell carcinoma, breast carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma (also called cholangioma and cholangiocarcinoma), chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epibulbar carcinoma, epidermoid carcinoma, carcinoma epitheliale adenoides, carcinoma exulcere, carcinoma fibrosum, gelatiniform carcinoma, gelatinous carcinoma, giant cell carcinoma, gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma (also called hepatoma, malignant hepatoma and hepatocarcinoma), Hurthle cell carcinoma, hyaline carcinoma, hypemephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma mastitoides, carcinoma medullare, medullary carcinoma, carcinoma melanodes, melanotic carcinoma, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, carcinoma nigrum, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, ovarian carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prostate carcinoma, renal cell carcinoma of kidney (also called adenocarcinoma of kidney and hypemephoroid carcinoma), reserve cell carcinoma, carcinoma sarcomatodes, scheinderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squarnous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, carcinoma vilosum. In particular non-limiting embodiments, the methods of the presently disclosed inventive concept(s) are used to treat subjects having cancer of the breast, cervix, ovary, prostate, lung, colon and rectum, pancreas, stomach or kidney.

Other conditions characterized by an abnormal mammalian cell proliferation to be treated by the methods described herein include, but are not limited to, sarcomas. Sarcomas are rare mesenchymal neoplasms that arise in bone and soft tissues. Different types of sarcomas are recognized and these include: liposarcomas (including myxoid liposarcomas and pleiomorphic liposarcomas), leiomyosarcomas, rhabdomyosarcomas, malignant peripheral nerve sheath tumors (also called malignant schwannomas, neurofibrosarcomas, or neurogenic sarcomas), Ewing's tumors (including Ewing's sarcoma of bone, extraskeletal Ewing's sarcoma, and primitive neuroectodermal tumor), synovial sarcoma, angiosarcomas, hemangiosarcomas, lymphangiosarcomas, Kaposi's sarcoma, hemangioendothelioma, fibrosarcoma, desmoid tumor (also called aggressive fibromatosis), dermatofibrosarcoma protuberans, malignant fibrous histiocytoma, hemangiopericytoma, malignant mesenchymoma, alveolar soft-part sarcoma, epithelioid sarcoma, clear cell sarcoma, desmoplastic small cell tumor, gastrointestinal stromal tumor (also known as GI stromal sarcoma), osteosarcoma (also known as osteogenic sarcoma)-skeletal and extraskeletal, and chondrosarcoma.

The methods of the presently disclosed inventive concept(s) also include the treatment of subjects with melanoma. Melanomas are tumors arising from the melanocytic system of the skin and other organs. Examples of melanoma include lentigo maligna melanoma, superficial spreading melanoma, nodular melanoma, and acral lentiginous melanoma.

Conditions characterized by an abnormal mammalian cell proliferation as noted are cancers including, but not limited to, biliary tract cancer, endometrial cancer, esophageal cancer, gastric cancer, intraepithelial neoplasms, including Bowen's disease and Paget's disease, liver cancer, oral cancer, including squamous cell carcinoma, sarcomas, including fibrosarcoma and osteosarcoma, skin cancer, including melanoma, Kaposi's sarcoma, testicular cancer, including germinal tumors (seminoma, non-seminoma (teratomas, choriocarcinomas)), stromal tumors and germ cell tumors, thyroid cancer, including thyroid adenocarcinoma and medullar carcinoma, and renal cancer including adenocarcinoma and Wilms tumor.

Further, the presently disclosed inventive concept(s) include treating a subject having an abnormal proliferation originating in bone, muscle or connective tissue. Exemplary conditions intended for treatment by the present methods include primary tumors (i.e., sarcomas) of bone and connective tissue. The methods also include treatment of subjects with metastatic tumors. In some embodiments, the metastatic tumors are of epithelial origin. Carcinomas may metastasize to bone, as has been observed with breast cancer, and liver, as is sometimes the case with colon cancer. The methods of the presently disclosed inventive concept(s) are intended to treat metastatic tumors regardless of the site of the metastasis and/or the site of the primary tumor. In particular non-limiting embodiments, the metastases treated by the present methods are of epithelial origin.

The presently disclosed inventive concept(s) include methods for inhibiting FAP-related angiogenesis in disorders in a subject having a pathology which requires angiogenesis. Angiogenesis is defined as the formation of new blood vessels. These disorders include conditions characterized by abnormal mammalian cell proliferation, such as cancerous conditions wherein overexpression of FAP associated with the tumors stimulates angiogenesis and rapid tumor growth, as well as non-cancer conditions including diabetic retinopathy, neovascular glaucoma and psoriasis.

In particular non-limiting embodiments, the present methods are aimed at inhibiting tumor angiogenesis. Tumor angiogenesis refers to the formation of new blood vessels in the vicinity or within a tumor mass. Solid tumor cancers require angiogenesis particularly for oxygen and nutrient supply. It has been previously shown that inhibition of angiogenesis in solid tumor can cause tumor regression in animal models. Thus in one aspect, the presently disclosed inventive concept(s) relate to methods for inhibiting angiogenesis by inhibiting the proliferation, migration or activation of endothelial cells and fibroblasts, wherein this angiogenesis is unrelated to wound healing in response to injury, infection or inflammation.

Thus, the present methods are intended for the treatment of diseases and processes that are mediated by angiogenesis including, but not limited to, hemangioma, solid tumors, tumor metastasis, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas and trachomas, Osler-Webber Syndrome, telangiectasia, myocardial angiogenesis, angiofibroma, plaque neovascularization, coronary collaterals, ischemic limb angiogenesis, corneal diseases, rubiosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, diabetic neovascularization, macular degeneration, keloids, ovulation, menstruation, and placentation.

The compositions and methods of the presently disclosed inventive concept(s) in certain instances may be useful for replacing existing surgical procedures or drug therapies, although in most instances the methods are useful in improving the efficacy of existing therapies for treating such conditions. Accordingly combination therapy may be used to treat the subjects. For example, the inhibitors may be administered to a subject in combination with another anti-proliferative (e.g., an anti-cancer) therapy. Suitable anti-cancer therapies include, but are not limited to, surgical procedures to remove the tumor mass, chemotherapy or localization radiation. The other anti-proliferative therapy may be administered before, concurrent with, or after treatment with the inhibitors of the presently disclosed inventive concept(s). There may also be a delay of several hours, days and in some instances weeks between the administration of the different treatments, such that the inhibitor may be administered before or after the other treatment.

As an example, the inhibitor may be administered in combination with surgery to remove an abnormal proliferative cell mass. As used herein, “in combination with surgery” means that the agent may be administered prior to, during or after the surgical procedure.

The subjects treated with the presently disclosed inhibitors may be treated in combination with other non-surgical anti-proliferative (e.g., anti-cancer) drug therapy. In one embodiment, the inhibitor may be administered in combination with an anti-cancer compound such as a cytostatic compound. A cytostatic compound is a compound (e.g., a nucleic acid, or a protein) that suppresses cell growth and/or proliferation. In some embodiments, the cytostatic compound is directed towards the malignant cells of a tumor. In yet other embodiments, the cytostatic compound is one which inhibits the growth and/or proliferation of vascular smooth muscle cells or fibroblasts.

Suitable anti-proliferative drugs or cytostatic compounds to be used in combination with the presently disclosed inhibitors include anti-cancer drugs. Numerous anti-cancer drugs which may be used are well known and include, but are not limited to: Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflornithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epipropidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta-I a; Interferon Gamma-I b; Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Metoprine; Meturedepa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin Sulfate; Perfosfamide; Pipobroman; Piposulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin; Prednimustine; Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol; Safingol Hydrochloride; Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin; Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Sulofenur; Talisomycin; Taxol; Taxotere; Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride; Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine; Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Tubulozole Hydrochloride; Uracil Mustard; Uredepa; Vapreotide; Verteporfin; Vinblastine Sulfate; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; and Zorubicin Hydrochloride.

Other anti-cancer drugs include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; acylfulvene; adecypenol; adozelesin; ALL-TK antagonists; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; anagrelide;

-   -   andrographolide; angiogenesis inhibitors; antagonist D;         antagonist G; antarelix; anti-dorsalizing morphogenetic         protein-1; antiestrogen; antineoplaston; antisense         oligonucleotides; aphidicolin glycinate; apoptosis gene         modulators; apoptosis regulators; apurinic acid;         ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane;         atrimustine; axinastatin 1; axinastatin 2; axinastatin 3;         azasetron; azatoxin; azatyrosine; baccatin III derivatives;         balanol; batimastat; BCR/ABL antagonists; benzochlorins;         benzoylstaurosporine; beta lactam derivatives; beta-alethine;         betaclamycin B; betulinic acid; bFGF inhibitor;         bisaziridinylspermine; bisnafide; bistratene A; breflate;         budotitane; buthionine sulfoximine; calcipotriol; calphostin C;         camptothecin derivatives; canarypox IL-2; capecitabine;         carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3;         CARN 700; cartilage derived inhibitor; casein kinase inhibitors         (ICOS); castanospermine; cecropin B; cetrorelix; chlorins;         chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin;         clomifene analogues; clotrimazole; collismycin A; collismycin B;         combretastatin A4; combretastatin analogue; conagenin;         crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A         derivatives; curacin A; cyclopentanthraquinones; cycloplatam;         cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin;         dacliximab; dehydrodidemnin B; deslorelin; dexifosfamide;         dexrazoxane; dexverapamil; didemnin B; didox;         diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-;         dioxamycin; diphenyl spiromustine; docosanol; dolasetron;         doxifluridine; dronabinol; duocarmycin SA; ebselen; ecomustine;         edelfosine; edrecolomab; eflomithine; elemene; emitefur;         epirubicin; epristeride; estramustine analogue; estrogen         agonists; estrogen antagonists; etanidazole; etoposide         phosphate; exemestane; filgrastim; finasteride; flavopiridol;         flezelastine; fluasterone; fludarabine; fluorodaunorunicin         hydrochloride; forfenimex; formestane; fotemustine; gadolinium         texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase         inhibitors; glutathione inhibitors; hepsulfam; heregulin;         hexamethylene bisacetamide; hypericin; ibandronic acid;         idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones;         imiquimod; immunostimulant peptides; insulin-like growth         factor-I receptor inhibitor; interferon agonists; interferons;         interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-;         irinotecan; iroplact; irsogladine; isobengazole;         isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F;         lamellarin-N triacetate; lanreotide; leinamycin; lenograstim;         lentinan sulfate; leptolstatin; leukemia inhibiting factor;         leukocyte alpha interferon; leuprolide+estrogen+progesterone;         leuprorelin; levamisole; liarozole; linear polyamine analogue;         lipophilic disaccharide peptide; lipophilic platinum compounds;         lissoclinamide 7; lobaplatin; lombricine; lometrexol;         lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan;         lutetium texaphyrin; lysofylline; lytic peptides; maitansine;         mannostatin A; marimastat; masoprocol; maspin; matrilysin         inhibitors; matrix metalloproteinase inhibitors; merbarone;         meterelin; methioninase; metoclopramide; MIF inhibitor;         mifepristone; miltefosine; mirimostim; mismatched double         stranded RNA; mitoguazone; mitolactol; mitomycin analogues;         mitonafide; mitotoxin fibroblast growth factor-saporin;         mofarotene; molgramostim; monoclonal antibody, human chorionic         gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk;         mopidamol; multiple drug resistance gene inhibitor; multiple         tumor suppressor 1-based therapy; mustard anti cancer compound;         mycaperoxide B; mycobacterial cell wall extract; myriaporone;         N-acetyldinaline; N-substituted benzamides; nafarelin;         nagrestip; naloxone+pentazocine; napavin; naphterpin;         nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral         endopeptidase; nilutamide; nisamycin; nitric oxide modulators;         nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide;         okicenone; oligonucleotides; onapristone; ondansetron;         ondansetron; oracin; oral cytokine inducer; osaterone;         oxaliplatin; oxaunomycin; paclitaxel analogues; paclitaxel         derivatives; palauamine; palmitoylrhizoxin; pamidronic acid;         panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase;         peldesine; pentosan polysulfate sodium; pentostatin; pentrozole;         perflubron; perfosfamide; perillyl alcohol; phenazinomycin;         phenylacetate; phosphatase inhibitors; picibanil; pilocarpine         hydrochloride; pirarubicin; piritrexim; placetin A; placetin B;         plasminogen activator inhibitor; platinum complex; platinum         compounds; platinum-triamine complex; porfimer sodium;         porfiromycin; propyl bis-acridone; prostaglandin J2; proteasome         inhibitors; protein A-based immune modulator; protein kinase C         inhibitor; protein kinase C inhibitors, microalgal; protein         tyrosine phosphatase inhibitors; purine nucleoside phosphorylase         inhibitors; purpurins; pyrazoloacridine; pyridoxylated         hemoglobin polyoxyethylene conjugate; raf antagonists;         raltitrexed; ramosetron; ras farnesyl protein transferase         inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine         demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes;         RII retinamide; rohitukine; romurtide; roquinimex; rubiginone         B1; ruboxyl; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi         1 mimetics; senescence derived inhibitor 1; sense         oligonucleotides; signal transduction inhibitors; signal         transduction modulators; single chain antigen binding protein;         sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate;         solverol; somatomedin binding protein; sonermin; sparfosic acid;         spicamycin D; spiromustine; splenopentin; spongistatin 1;         squalamine; stem cell inhibitor; stem-cell division inhibitors;         stipiamide; stromelysin inhibitors; sulfinosine; superactive         vasoactive intestinal peptide antagonist; suradista; suramin;         swainsonine; synthetic glycosaminoglycans; tallimustine;         tamoxifen methiodide; tauromustine; tazarotene; tecogalan         sodium; tegafur; tellurapyrylium; telomerase inhibitors;         temozolomide; tetrachlorodecaoxide; tetrazomine; thaliblastine;         thalidomide; thiocoraline; thrombopoietin; thrombopoietin         mimetic; thymalfasin; thymopoietin receptor agonist;         thymotrinan; thyroid stimulating hormone; tin ethyl         etiopurpurin; titanocene dichloride; topsentin; toremifene;         totipotent stem cell factor; translation inhibitors; tretinoin;         triacetyluridine; triciribine; tropisetron; turosteride;         tyrosine kinase inhibitors; tyrphostins; UBC inhibitors;         ubenimex; urogenital sinus-derived growth inhibitory factor;         urokinase receptor antagonists; variolin B; vector system,         erythrocyte gene therapy; velaresol; veramine; verdins;         vinorelbine; vinxaltine; vitaxin; zanoterone; zilascorb; and         zinostatin stimalamer.

Anti-cancer supplementary potentiating compounds include, but are not limited to: Tricyclic anti-depressant drugs (e.g., imipramine, desipramine, amitryptyline, clomipramine, trimipramine, doxepin, nortriptyline, protriptyline, amoxapine and maprotiline); non-tricyclic anti-depressant drugs (e.g., sertraline, trazodone and citalopram); Ca²⁺ antagonists (e.g., verapamil, nifedipine, nitrendipine and caroverine); Calmodulin inhibitors (e.g., prenylamine, trifluoroperazine and clomipramine); Amphotericin B; Triparanol analogues (e.g., tamoxifen); antiarrhythmic drugs (e.g., quinidine); antihypertensive drugs (e.g., reserpine); Thiol depleters (e.g., buthionine and sulfoximine) and multiple drug resistance reducing compounds such as Cremaphor EL.

Other compounds which are useful in combination therapy for the purposes of the presently disclosed inventive concept(s) include, but are not limited to, the antiproliferation compound Piritrexim Isethionate; the antiprostatic hypertrophy compound Sitogluside; the benign prostatic hyperplasia therapy compound Tamsulosin Hydrochloride; the prostate growth inhibitor Pentomone; radioactive compounds such as Fibrinogen I 125, Fludeoxyglucose F 18, Fluorodopa F 18, Insulin I 125, Insulin I 131, Iobenguane I 123, Iodipamide Sodium I 131, Iodoantipyrine I 131, Iodocholesterol I 131, Iodohippurate Sodium I 123, Iodohippurate Sodium I 125, Iodohippurate Sodium I 131, Iodopyracet I 125, Iodopyracet I 131, Iofetamine Hydrochloride I 123, Iomethin I 125, Iomethin I 131, Iothalamate Sodium I 125, Iothalamate Sodium I 131, Iotyrosine I 131, Liothyronine I 125, Liothyronine I 131, Merisoprol Acetate Hg 197, Merisoprol Acetate Hg 203, Merisoprol Hg 197, Selenomethionine Se 75, Technetium Tc 99m Antimony Trisulfide Colloid, Technetium Tc 99m Bicisate, Technetium Tc 99m Disofenin, Technetium Tc 99m Etidronate, Technetium Tc 99m Exametazime, Technetium Tc 99m Furifosmin, Technetium Tc 99m Gluceptate, Technetium Tc 99m Lidofenin, Technetium Tc 99m Mebrofenin, Technetium Tc 99m Medronate, Technetium Tc 99m Medronate Disodium, Technetium Tc 99m Mertiatide, Technetium Tc 99m Oxidronate, Technetium Tc 99m Pentetate, Technetium Tc 99m Pentetate Calcium Trisodium, Technetium Tc 99m Sestamibi, Technetium Tc 99m Siboroxime, Technetium Tc 99m Succimer, Technetium Tc 99m Sulfur Colloid, Technetium Tc 99m Teboroxime, Technetium Tc 99m Tetrofosmin, Technetium Tc 99m Tiatide, Thyroxine I 125, Thyroxine I 131, Tolpovidone I 131, Triolein I 125 and Triolein I 131.

According to the methods of the presently disclosed inventive concept(s), the compounds may be administered prior to, concurrent with, or following the other anti-cancer compounds. The administration schedule may involve administering the different agents in an alternating fashion. In other embodiments, the inhibitor may be delivered before and during, or during and after, or before and after treatment with other therapies. In some cases, the inhibitor is administered more than 24 hours before the administration of the other anti-proliferative treatment. In other embodiments, more than one anti-proliferative therapy may be administered to a subject. For example, the subject may receive the present inhibitors, in combination with both surgery and at least one other anti-proliferative compound. Alternatively, the inhibitor may be administered in combination with more than one anti-cancer drug.

Other compounds useful in combination therapies with the inhibitor compounds of the presently disclosed inventive concept(s) include, but are not limited to, anti-angiogenic compounds such as angiostatin, endostatin, fumagillin, non-glucocorticoid steroids and heparin or heparin fragments and antibodies to one or more angiogenic peptides such as α-FGF, β-FGF, VEGF, IL-8 and GM-CSF. These latter anti-angiogenic compounds may be administered along with the inhibitor compounds of the presently disclosed inventive concept(s) for the purpose of inhibiting proliferation or inhibiting angiogenesis in all of the aforementioned conditions as described herein. In certain embodiments, the inhibitors may be administered in combination with an anti-angiogenic compound and at least one of the anti-proliferative therapies described above including surgery or anti-proliferative drug therapy.

The present compounds are administered in therapeutically effective amounts. An effective amount is a dosage of the inhibitor sufficient to provide a therapeutically or medically desirable result or effect in the subject to which the compound is administered. The effective amount will vary with the particular condition being treated, the age and physical condition of the subject being treated, the severity of the condition, the duration of the treatment, the nature of the concurrent or combination therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. For example, in connection with methods directed towards treating subjects having a condition characterized by abnormal cell proliferation, an effective amount to inhibit proliferation would be an amount sufficient to reduce or halt altogether the abnormal cell proliferation so as to slow or halt the development of or the progression of a cell mass such as, for example, a tumor. As used in the embodiments, “inhibit” embraces all of the foregoing.

In other embodiments, a therapeutically effective amount will be an amount necessary to extend the dormancy of micrometastases or to stabilize any residual primary tumor cells following surgical or drug therapy.

Generally, a therapeutically effective amount will vary with the subject's age, condition, and sex, as well as the nature and extent of the disease in the subject, all of which can be determined by one of ordinary skill in the art. The dosage may be adjusted by the individual physician or veterinarian, particularly in the event of any complication. A therapeutically effective amount is typically, but not limited to, an amount in a range from 0.1 μg/kg to about 2000 mg/kg, or from 1.0 μg/kg to about 1000 mg/kg, or from about 0.1 mg/kg to about 500 mg/kg, or from about 1.0 mg/kg to about 100 mg/kg, in one or more dose administrations daily, for one or more days. If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses for example administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In some embodiments, the inhibitors are administered for more than 7 days, more than 10 days, more than 14 days and more than 20 days. In still other embodiments, the inhibitor is administered over a period of weeks, or months. In still other embodiments, the inhibitor is delivered on alternate days. For example, the agent is delivered every two days, or every three days, or every four days, or every five days, or every six days, or every week, or every month.

The inhibitors of the presently disclosed inventive concept(s) can also be administered in prophylactically effective amounts, particularly in subjects diagnosed with benign or pre-malignant tumors. In these instances, the inhibitors are administered in an amount effective to prevent the development of an abnormal mammalian cell proliferative mass or to prevent angiogenesis in the solid tumor mass, depending on the embodiment. The inhibitors may also be administered in an amount effective to prevent metastasis of cells from a tumor to other tissues in the body. In these latter embodiments, the presently disclosed inventive concept(s) include methods of preventing the metastatic spread of a primary tumor.

According to another aspect of the presently disclosed inventive concept(s), a kit is provided. The kit is a package which houses a container which contains an inhibitor of the presently disclosed inventive concept(s) and also includes instructions for administering the inhibitor to a subject having a condition characterized by an abnormal mammalian cell proliferation. The kit may optionally also contain one or more other anti-proliferative compounds or one or more anti-angiogenic compounds for use in combination therapies as described herein.

The compounds of the presently disclosed inventive concept(s) may be administered alone or in combination with the above-described drug therapies by a variety of administration routes available. The particular mode selected will depend, of course, upon the compound selected, the condition being treated, the severity of the condition, whether the treatment is therapeutic or prophylactic, and the dosage required for efficacy. The methods of the presently disclosed inventive concept(s), generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. The administration may, for example, be oral, intraperitoneal, intra-cavity such as rectal or vaginal, transdermal, topical, nasal, inhalation, mucosal, interdermal, or parenteral routes. The term “parenteral” includes subcutaneous, intravenous, intramuscular, or infusion. Intravenous or intramuscular routes may not particularly suitable for long term therapy and prophylaxis. In certain embodiments, however, it may be appropriate to administer the compound in a continuous infusion every several days, or once a week, or every several weeks, or once a month. In certain non-limiting embodiments, intravenous or intramuscular routes may be desired in emergency situations. Oral administration may be used for prophylactic treatment because of the convenience to the patient as well as the dosing schedule. Likewise, sustained release devices as described herein may be useful in certain embodiments for prophylactic or post surgery treatment, for example.

When using the compounds of the presently disclosed inventive concept(s) in subjects in whom the primary site of abnormal proliferation is well delineated and easily accessible, direct administration to the site may be desired (in certain non-limiting embodiments), provided the tumor has not already metastasized. For example (but not by way of limitation), administration by inhalation for lung tumors or by suppositories in the treatment of cervical, ovarian or rectal tumors may be desired. Likewise, melanoma, for example, may be treated with the compound via topical administration in and around the area of the lesion. In still other embodiments aimed at the treatment of subjects with breast or prostate cancer, the compounds may be delivered by injection directly into the tissue with, for example, a biopsy needle and syringe.

In particular non-limiting embodiments, systemic administration may be desired in some instances such as, for example, if the subject is known to have or is suspected of having metastases. In this way, all tumor sites, whether primary or secondary may receive the compound. Systemic delivery may be accomplished through for example, oral or parenteral administration. Inhalation may be used in either systemic or local delivery, as described herein.

In certain non-limiting embodiments, compositions of the compound for parenteral administration may desirably include, but are not limited to, sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include, for example, sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating compounds, and inert gases and the like. The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy.

In certain non-limiting embodiments, compositions suitable for oral administration desirably comprise discrete units, such as (but not limited to) capsules, tablets, lozenges, each containing a predetermined amount of the inhibitor. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion. In yet other non-limiting embodiments, the desired vehicle is a biocompatible microparticle or implant that is suitable for implantation into the mammalian recipient.

In other embodiments of the presently disclosed inventive concept(s), the compound is targeted to a site of abnormal cell proliferation, such as, a tumor, through the use of a targeting compound specific for a particular tissue or tumor type. The compounds of the presently disclosed inventive concept(s) may be targeted to primary or in some instances, secondary (i.e., metastatic) lesions through the use of targeting compounds which preferentially recognize a cell surface marker. The targeting compound may be directly conjugated to the compounds of the presently disclosed inventive concept(s) via a covalent linkage. The compound may be indirectly conjugated to a targeting compound via a linker. Alternatively, the targeting compound may be conjugated or associated with an intermediary compound such as, for example, a liposome within which the inhibitor is encapsulated. Liposomes are artificial membrane vessels which are useful as a delivery vector in vivo or in vitro. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2-4.0 μm can encapsulate large macromolecules. Liposomes may be targeted to a particular tissue, such as the vascular cell wall, by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. In still other embodiments, the targeting compound may be loosely associated with the compounds of the presently disclosed inventive concept(s), such as within a microparticle comprising a polymer, the compound of the presently disclosed inventive concept(s) and the targeting compound.

Targeting compounds useful according to the methods of the presently disclosed inventive concept(s) are those which direct the compound to a site of abnormal proliferation such as a tumor site. The targeting compound of choice will depend upon the nature of the tumor or the tissue origin of the metastasis. In some instances it may be desirable to target the compound to the tissue in which the tumor is located. For example, the compounds can be delivered to breast epithelium by using a targeting compound specific for breast tissue. In particular non-limiting embodiments, the target is specific for malignant breast epithelium. Examples of compounds which may localize to malignant breast epithelium include, but are not limited to, estrogen and progesterone, epithelial growth factor (EGF) and HER-2/neu ligand, among others. The HER-2/neu ligand may also be used to target compounds to ovarian cancers. Ovarian cancers are also known to express EGFR and c-fms, and thus could be targeted through the use of ligands for either receptor. In the case of c-fms which is also expressed by macrophages and monocytes, targeted delivery to an ovarian cancer may require a combination of local administration such as a vaginal suppository as well as a targeting compound. Prostate cancers can be targeted using compounds such as peptides (e.g., antibodies or antibody fragments) which bind to prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Other markers which may be used for targeting of the agent to specific tissues include, for example, in liver: HGF, insulin-like growth factor I, II, insulin, OV-6, HEA-125, hyaluronic acid, collagen, N-terminal propeptide of collagen type III, mannose/N-acetylglucosamine, asialoglycoprotein, tissue plasminogen activator, low density lipoprotein, carcinoembryonic antigen; in kidney cells: angiotensin II, vasopressin, antibodies to CD44v6; in keratinocytes and skin fibroblasts: KGF, very low density lipoprotein, RGD-containing peptides, collagen, laminin; in melanocytes: kit ligand; in gut: cobalamin-intrinsic factor, heat stable enterotoxin of E. Coli; in breast epithelium: heregulin, prolactin, transferrin, cadherin-11. Other markers specific to particular tissues are available and would be known to one of ordinary skill in the art.

In still other embodiments, the compounds of the presently disclosed inventive concept(s) may be targeted to fibroblasts specifically, via ligands or binding partners for fibroblast specific markers. Examples of these markers include, but are not limited to fibroblast growth factors (FGF) and platelet derived growth factor (PDGF). In some embodiments, it is desirable to target the compound to FAP specifically through the use of binding peptides for FAP which do not interfere with inhibition by the compound of the presently disclosed inventive concept(s).

Other embodiments of the presently disclosed inventive concept(s) include pharmaceutically acceptable compositions which comprise a therapeutically-effective amount of one or more of the compounds described herein, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. As described in detail below, the pharmaceutically acceptable compositions may be specially formulated for administration in solid or liquid form, including, but not limited to, those adapted for the following: (1) oral administration, for example, aqueous or non-aqueous solutions or suspensions, tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase “pharmaceutically-acceptable carrier” as used herein means a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; and (22) other non-toxic compatible substances employed in pharmaceutical formulations.

As set forth above, in certain embodiments, the compounds of the presently disclosed inventive concept(s) contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable acids. The term “pharmaceutically-acceptable salts” in this respect, refers to the relatively non-toxic, inorganic and organic acid addition salts of the compounds. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting a purified compound of the presently disclosed inventive concept(s) in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed during subsequent purification. Representative salts include, but are not limited to, the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.

The pharmaceutically acceptable salts of the subject compounds include, but are not limited to, the conventional nontoxic salts or quaternary ammonium salts of the compounds, e.g., from non-toxic organic or inorganic acids. For example, such conventional nontoxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.

In other cases, the compounds of the presently disclosed inventive concept(s) may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable bases. The term “pharmaceutically-acceptable salts” in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the presently disclosed inventive concept(s). These salts can likewise be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically-acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include, but are not limited to, the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include, but are not limited to, ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.

Wetting agents, emulsifiers and lubricants, including, but not limited to, sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Examples of pharmaceutically-acceptable antioxidants include, but are not limited to: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

As noted above, formulations of the presently disclosed inventive concept(s) include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, such as (but not limited to) from about 5 percent to about 70 percent, and in particular (but not by way of limitation) from about 10 percent to about 30 percent.

In certain embodiments, a formulation of the presently disclosed inventive concept(s) comprises an excipient selected from the group consisting of cyclodextrins, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides.

Methods of preparing these formulations or compositions may include the step of bringing into association a compound of the presently disclosed inventive concept(s) with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the presently disclosed inventive concept(s) with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

Formulations of the presently disclosed inventive concept(s) suitable for oral administration may be, but are not limited to, the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the presently disclosed inventive concept(s) as an active ingredient. A compound of the presently disclosed inventive concept(s) may also be administered as a bolus, or paste.

In solid dosage forms of the presently disclosed inventive concept(s) for oral administration (capsules, tablets, pills, powders, granules and the like), the compound or compounds are mixed with one or more pharmaceutically-acceptable carriers, including, but not limited to, sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

The tablets, and other solid dosage forms of the pharmaceutical compositions of the presently disclosed inventive concept(s), such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the compound or compounds therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or in certain non-limiting embodiments, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

Liquid dosage forms for oral administration of the compounds of the presently disclosed inventive concept(s) include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Formulations of the pharmaceutical compositions of the presently disclosed inventive concept(s) for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the presently disclosed inventive concept(s) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.

Formulations of the presently disclosed inventive concept(s) which are suitable for vaginal administration also include, but are not limited to, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

Dosage forms for the topical or transdermal administration of a compound of the presently disclosed inventive concept(s) include, but are not limited to, powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

The ointments, pastes, creams and gels may contain, for example, in addition to an active compound of the presently disclosed inventive concept(s), excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, for example, in addition to a compound of the presently disclosed inventive concept(s), excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

Transdermal patches have the added advantage of providing controlled delivery of a compound of the presently disclosed inventive concept(s) to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.

Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of the presently disclosed inventive concept(s).

Pharmaceutical compositions of the presently disclosed inventive concept(s) suitable for parenteral administration comprise one or more compounds of the presently disclosed inventive concept(s) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the presently disclosed inventive concept(s) include, but are not limited to, water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.

When the compounds of the presently disclosed inventive concept(s) are administered as pharmaceuticals, to human or animal subjects, they are generally given as a pharmaceutical composition containing, for example, 0.01% to 99.5% (such as (but not limited to) 0.5 to 90%) of the compound (with or without other compounds given adjunctively in combination with a pharmaceutically acceptable carrier).

The preparations of the presently disclosed inventive concept(s) may be given, for example, orally, parenterally, topically, or rectally as explained above. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, by injection, infusion or inhalation, topical by lotion or ointment, and rectal by suppositories.

The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subeuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

Regardless of the route of administration selected, the compounds of the presently disclosed inventive concept(s), which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the presently disclosed inventive concept(s), are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art. Actual dosage levels of the active ingredients in the pharmaceutical compositions of the presently disclosed inventive concept(s) may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the presently disclosed inventive concept(s) employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the presently disclosed inventive concept(s) employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

While it is possible for compounds of the presently disclosed inventive concept(s) to be administered alone, it may be desirable (but not by way of limitation) to administer the compound as a pharmaceutical formulation (composition).

The term “treatment” as used herein is intended to encompass also prophylaxis, therapy and cure.

As noted, particular non-limiting amounts and modes of administration are able to be determined by one skilled in the art. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the disease state to be treated, the stage of the disease, and other relevant circumstances using formulation technology known in the art, described, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co.

Pharmaceutical compositions can be manufactured utilizing techniques known in the art. Typically the therapeutically effective amount of the compound will be admixed with a pharmaceutically acceptable carrier as described elsewhere herein.

In one embodiment, the half-life of the compounds described herein can be extended by their being conjugated to other molecules such as polymers using methods known in the art to form drug-polymer conjugates. For example, the molecules can be bound to molecules of inert polymers known in the art, such as a molecule of polyethylene glycol (PEG) in a method known as “pegylation”. Pegylation can therefore extend the in vivo lifetime and thus therapeutic effectiveness of the molecule.

PEG molecules can be modified by functional groups, for example as shown in Harris et al., “Pegylation, A Novel Process for Modifying Phararmacokinetics”, Clin Pharmacokinet, 2001:40(7); 539-551, and the amino terminal end of the molecule, or cysteine residue if present, or other linking amino acid therein can be linked thereto, wherein the PEG molecule can carry one or a plurality of one or more types of molecules.

By “polyethylene glycol” or “PEG” is meant a polyalkylene glycol compound or a derivative thereof, with or without coupling agents or derviatization with coupling or activating moeities (e.g., with thiol, triflate, tresylate, azirdine, oxirane, or in certain non-limiting embodiments, with a maleimide moiety). Compounds such as maleimido monomethoxy PEG are exemplary or activated PEG compounds of the presently disclosed inventive concept(s). Other polyalkylene glycol compounds, such as polypropylene glycol, may be used in the presently disclosed inventive concept(s). Other appropriate polymer conjugates include, but are not limited to, non-polypeptide polymers, charged or neutral polymers of the following types: dextran, colominic acids or other carbohydrate based polymers, biotin deriviatives and dendrimers, for example. The term PEG is also meant to include other polymers of the class polyalkylene oxides.

The PEG can be linked to any N-terminal amino acid of the molecule described herein and/or can be linked to an amino acid residue downstream of the N-terminal amino acid, such as lysine, histidine, tryptophan, aspartic acid, glutamic acid, and cysteine, for example or other such amino acids known to those of skill in the art.

The PEG carrier moiety attached to the peptide may range in molecular weight from about 200 to 20,000 MW. In certain non-limiting embodiments, the PEG moiety will be from about 1,000 to 8,000 MW, such as (but not limited to) from about 3,250 to 5,000 MW, and in a particular non-limiting embodiment, about 5,000 MW. The actual number of PEG molecules covalently bound per molecule of the presently disclosed inventive concept(s) may vary widely depending upon the desired stability (i.e. serum half-life). Molecules contemplated herein can be linked to PEG molecules using techniques shown, for example (but not limited to), in U.S. Pat. Nos. 4,179,337; 5,382,657; 5,972,885; 6,177,087; 6,165,509; 5,766,897; and 6,217,869; the specifications and drawings each of which are hereby expressly incorporated herein by reference.

Alternatively, it is possible to entrap the molecules in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatine-microcapsules and poly-(methylmethacylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules), or in macroemulsions. Such techniques are disclosed in the latest edition of Remington's Pharmaceutical Sciences.

U.S. Pat. No. 4,789,734 describe methods for encapsulating biochemicals in liposomes and is hereby expressly incorporated by reference herein. Essentially, the material is dissolved in an aqueous solution, the appropriate phospholipids and lipids added, along with surfactants if required, and the material dialyzed or sonicated, as necessary. A review of known methods is by G. Gregoriadis, Chapter 14. “Liposomes”, Drug Carriers in Biology and Medicine, pp. 287-341 (Academic Press, 1979). Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract directly into the blood stream. Alternatively, the agents can be incorporated and the microspheres, or composite of microspheres, implanted for slow release over a period of time, ranging from days to months. See, for example, U.S. Pat. Nos. 4,906,474; 4,925,673; and 3,625,214 which are incorporated by reference herein.

When the composition is to be used as an injectable material, it can be formulated into a conventional injectable carrier. Suitable carriers include biocompatible and pharmaceutically acceptable phosphate buffered saline solutions, which in certain non-limiting embodiments, are isotonic.

For reconstitution of a lyophilized product in accordance with the presently disclosed inventive concept(s), one may employ a sterile diluent, which may contain materials generally recognized for approximating physiological conditions and/or as required by governmental regulation. In this respect, the sterile diluent may contain a buffering agent to obtain a physiologically acceptable pH, such as sodium chloride, saline, phosphate-buffered saline, and/or other substances which are physiologically acceptable and/or safe for use. In general, the material for intravenous injection in humans should conform to regulations established by the Food and Drug Administration, which are available to those in the field.

The pharmaceutical composition may also be in the form of an aqueous solution containing many of the same substances as described above for the reconstitution of a lyophilized product.

The compounds can also be administered as a pharmaceutically acceptable acid- or base-addition salt, formed by reaction with inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.

In summary, utilities of the inhibitor or substrate compounds of the presently disclosed inventive concept(s) include, but are not limited to:

-   -   (1) prevention or reduction of atherosclerotic plaque         development and progression, especially in patients at high         risk;     -   (2) prevention or reduction of the development of arterial or         venous blood clot formation (atherothrombotic and venous thrombi         disorders), especially in conditions recognized as high risk for         such clots, i.e. heart attack or stroke;     -   (3) enhanced maintenance of vessel patency by continuous         administration of the inhibitor of APCE, alternatively in         association with simultaneous administration of low doses of         plasminogen activator drugs;     -   (4) prevention or reduction of fibrin formation where it may         cause persistent acute or chronic symptoms in association with         inflammatory conditions such as all forms of arthritis, organ         fibrosis, undesirable scarring, and cancer and its metastases;     -   (5) reduction of the risk of bleeding as a hyperfibrinolytic         state is induced, given that α₂AP_(pro) inhibits plasmin in         solution state as well as α₂AP_(act), when not crosslinked into         fibrin;     -   (6) aiding in the prevention and therapy of fibrin deposits         interfering with organ function as might be seen in         atherothrombotic disease, such as coronary artery thrombosis,         stroke, pulmonary embolism, all other forms of arterial and         venous thromboses, inflammatory conditions, and cancer and its         metastases;     -   (7) promoting fibrin digestion in vivo, comprising administering         to a subject an effective quantity of an inhibitor of         antiplasmin cleaving enzyme;     -   (8) inhibiting antiplasmin cleaving enzyme or FAP on cell         surfaces by binding to or blocking the α₂-antiplasmin binding         site, or α₂-antiplasmin pro-asn cleaving site of antiplasmin         cleaving enzyme or FAP;     -   (9) enhancing fibrin digestion in vivo, comprising providing to         a subject in need of clot digestion or clot prevention,         simultaneously or in sequence, a quantity of plasminogen         activator and an inhibitor of antiplasmin cleaving enzyme,         wherein the quantity of plasminogen activator is less than the         amount provided in standard therapeutic protocol absent the         inhibitor of antiplasmin cleaving enzyme; and     -   (10) administering the APCE/FAP inhibitor or a         chemotherapeutic-bearing APCE substrate to a subject to treat         various conditions involving abnormal cell proliferation which         involve FAP;     -   (11) determining whether a subject has a Trp6 or Arg6         polymorphism in α₂-antiplasmin;     -   (12) screening for inhibitors of antiplasmin cleaving enzyme and         FAP by using an APCE substrate with APCE or FAP;     -   (13) the compounds can be used in in vitro assays based on         cancer cell lines to determine the role of FAP at various stages         of pathogenesis of FAP-related cancers; and     -   (14) use of a compound having Formula Ia as a delivery or         targeting agent to FAP or APCE.

In further summary of the presently disclosed inventive concept(s), the following embodiments include:

A compound having the formula:

B-Xaa₁-Sp-Xaa₂-Cyc  (Formula I)

-   -   wherein:         -   B is a protecting group or is absent;         -   Xaa₁ is a positively-charged amino-acid;         -   Sp is a spacer molecule having a length in the range of 0.3             nm to 2.5 nm;         -   Xaa₂ is glycine, D-alanine, D-serine, or D-threonine; and         -   Cyc is a carbocyclic or heterocyclic compound.

In this embodiment Xaa₁ may comprise, for example, α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine, β-homoarginine, homoarginine, lysine, homolysine, β-homolysine, or histidine. Sp may comprise at least one of γ-aminobutyric acid, ε-aminocaproic acid, 8-amino-3,6-dioxaoctanoic acid, 11-amino-3,6,9-trioxaundecanoic acid, 14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid; 5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid; 8-aminooctanoic acid; 3-(aminooxy)acetic acid, β-alanine, gly, ala, thr, trp, tyr, met, leu, ile, val, ser, proline, PEG_(n) (n=1-6), PPG_(n) (n=1-6) amino-PEG_(n)-carboxy (n=1-6), amino-PPG_(n)-carboxy (n=1-6), or a combination of any of the above. B may comprise at least one of aminobenzoyl (Abz), acetyl (Ac), benzoyl (Bz), benzyloxycarbonyl (Z), τ-Butyloxycarbonyl (Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate (Pyr), Phenylalanine, a 1-3 mer peptide, and Succinyl (Suc). Cyc may comprise any compound of Table 1, including a 4, 5, 6, or 7-member carbon carbocycle, or a 4, 5, 6, or 7-member carbon heterocycle. The carbon heterocycle may comprise a nitrogen heteroatom. Further, Cyc may comprise a boronyl proline, proline carbonitrile, nitrile pyrrolidone, or cyanopyrrolidine. Sp may comprise an amino-PEG_(n)-carboxy group or an amino-PPG_(n)-carboxy group, wherein n=1-6. The compound may comprise an isostere bond between Xaa₁ and Sp. Xaa₂ may be glycine, D-alanine, D-serine, or D-threonine. Sp may have a length in a range of 0.6 nm to 1.75 nm. The compound may comprise a 1-10mer peptide or oligopeptide extending from Cyc in the C-terminal direction. The compound may bind to the active site of APCE at a Ki<20 nM and to DPPIV at a Ki>1000 nM for example. The compound may comprise part of a composition which is disposed within a pharmaceutically-acceptable carrier or vehicle.

A compound cleavable by α₂-antiplasmin cleaving enzyme, comprising:

Xaa₁-Sp-Xaa₂-Pro-Xaa₃  (Formula II)

-   -   wherein:         -   Xaa₁ is a positively-charged amino-acid;         -   Sp is a spacer molecule having a length in the range of 0.3             nm to 2.5 nm;         -   Xaa₂ is glycine, alanine, serine or threonine; and         -   Pro is proline; and         -   Xaa₃ is selected from asn, ser, gly, ala, val, leu, ile,             met, phe, tyr, trp, thr, glu, asp, gln, his, and arg; and         -   wherein the compound comprises of no more than 28 amino             acids.

The compound may comprise a 1-8mer oligopeptide extending from Xaa₁ in the N-terminal direction, and/or a 1-10mer oligopeptide extending from Xaa₃ in the C-terminal direction. The compound may comprise a quenching group and a fluorophore on opposite sides of the Xaa₂-Pro bond, or a reporter group attached to Xaa₃. Xaa₂ may be glycine, D-alanine, D-serine, or D-threonine. Xaa₁ may comprise α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine, β-homoarginine, homoarginine, lysine, homolysine, β-homolysine, or histidine. Sp may comprise at least one of γ-aminobutyric acid, ε-aminocaproic acid, 8-amino-3,6-dioxaoctanoic acid, 11-amino-3,6,9-trioxaundecanoic acid, 14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid; 5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid; 8-aminooctanoic acid; 3-(aminooxy)acetic acid, β-alanine, gly, ala, thr, trp, tyr, met, leu, ile, val, ser, proline, PEG_(n) (n=1-6), PPG_(n) (n=1-6) amino-PEG_(n)-carboxy (n=1-6), amino-PPG_(n)-carboxy (n=1-6), or a combination of any of the above.

A method of screening for inhibitors of antiplasmin cleaving enzyme (APCE), comprising:

-   -   providing a substrate compound which is cleavable by         α₂-antiplasmin cleaving enzyme, and which comprises a P₁-P₁′         bond, and has signaling activity when cleaved by the APCE,         wherein the P₁ comprises a proline, the P₁′ comprises any amino         acid which provides a cleavable P₁-P₁′ bond, and having a P₂         residue comprising glycine, D-alanine, D-serine, or D-threonine;     -   providing a quantity of α₂-antiplasmin cleaving enzyme;     -   exposing the α₂-antiplasmin cleaving enzyme to an α₂-antiplasmin         cleaving enzyme inhibitor candidate to form a test mixture;     -   combining the test mixture with the substrate compound; and     -   measuring the signal emitted from the test mixture for         identifying when the α₂-antiplasmin cleaving enzyme inhibitor         candidate inhibits or fails to inhibit the activity of         α₂-antiplasmin cleaving enzyme.

In this method the substrate compound may comprise:

Xaa₁-Sp-Xaa₂-Pro-Xaa₃  (Formula II)

-   -   wherein:         -   Xaa₁ is a positively-charged amino-acid;         -   Sp is a spacer molecule having a length in a range of 0.3 nm             to 2.5 nm;         -   Xaa₂ is gly, D-ala, or D-ser;         -   Pro is proline; and         -   Xaa₃ is selected from asn, ser, gly, ala, val, leu, ile,             met, phe, tyr, trp, thr, glu, asp, gin, his, and arg or any             other amino acid which when linked to the proline provides a             bond cleavable by APCE.

The substrate compound of this method may comprise a 1-8mer oligopeptide extending from Xaa₁ in the N-terminal direction, and/or a 1-10mer oligopeptide extending from Xaa₃ in the C-terminal direction. The compound may comprise a quenching group and a fluorophore on opposite sides of the Xaa₂-Pro bond, or a reporter group attached to Xaa₃. Xaa₁ may comprise α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine, β-homoarginine, homoarginine, lysine, homolysine, β-homolysine, or histidine. Sp may comprise at least one of γ-aminobutyric acid, ε-aminocaproic acid, 8-amino-3,6-dioxaoctanoic acid, 11-amino-3,6,9-trioxaundecanoic acid, 14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid; 5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid; 8-aminooctanoic acid; 3-(aminooxy)acetic acid, β-alanine, gly, ala, thr, trp, tyr, met, leu, ile, val, ser, proline, PEG_(n) (n=1-6), PPG_(n) (n=1-6), amino-PEG_(n)-carboxy (n=1-6), amino-PPG_(n)-carboxy (n=1-6), or a combination of any of the above.

A method of inhibiting activity of cell surface Fibroblast Activation Protein alpha (FAPα), comprising:

-   -   providing a compound comprising the formula:

B-Xaa₁-Sp-Xaa₂-Cyc  (Formula I)

-   -   -   wherein:             -   B is a protecting group or is absent;             -   Xaa₁ is a positively-charged amino-acid;             -   Sp is a spacer molecule having a length in a range of                 0.3 nm to 2.5 nm;             -   Xaa₂ is glycine, D-alanine, D-serine, or D-threonine;             -   Cyc is a carbocyclic or heterocyclic compound; and

    -   exposing cells having cell surface FAPα to the compound.

In this method the compound may have a Ki<20 nM for FAP and a Ki>1000 nM for dipeptidylpeptidase IV (DPPIV). The compound may be disposed in a pharmaceutically-acceptable carrier. B may comprise at least one of aminobenzoyl (Abz), acetyl (Ac), benzoyl (Bz), benzyloxycarbonyl (Z), τ-Butyloxycarbonyl (Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate (Pyr), Phenylalanine, a 1-3 mer peptide, and Succinyl (Suc). Xaa₁ may comprise α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine, β-homoarginine, homoarginine, lysine, homolysine, β-homolysine, or histidine. Sp may comprise at least one of γ-aminobutyric acid, ε-aminocaproic acid, 8-amino-3,6-dioxaoctanoic acid, 11-amino-3,6,9-trioxaundecanoic acid, 14-amino-3,6,9,12-tetraoxatetra-decanoic acid; α-aminobutyric acid; 5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid; 8-aminooctanoic acid; 3-(aminooxy)acetic acid, β-alanine, gly, ala, thr, trp, tyr, met, leu, ile, val, ser, proline, PEG_(n) (n=1-6), PPG_(n) (n=1-6), amino-PEG_(n)-carboxy (n=1-6), amino-PPG_(n)-carboxy (n=1-6), or a combination of any of the above. Xaa₂ may be glycine, D-alanine, D-serine, or D-threonine. Cyc may be a 4, 5, 6, or 7-member carbon carbocycle or may be a 4, 5, 6, or 7-member carbon heterocycle. When Cyc is carbon heterocycle, it may comprise a nitrogen heteroatom. Cyc may be a boronyl proline, proline carbonitrile, nitrile pyrrolidone, or cyanopyrrolidine or a compound from Table 1. Sp may be a PEG_(n), a PPG_(n), an amino-PEG_(n)-carboxy group or an amino-PPG_(n)-carboxy group, wherein n=1-6. The compound may comprise an isostere bond between Xaa₁ and Sp. Sp may have a length in a range of 0.6 nm to 1.75 nm. The compound may comprise a 1-10mer peptide or oligopeptide extending from Cyc in the C-terminal direction. The cells are any which have cell surface FAP including, but not limited to, fibroblast cells, myofibroblast cells and cancer cells.

All of the assay methods listed herein are well within the ability of one of ordinary skill in the art given the teachings provided herein.

All references, patents and patent applications cited herein are hereby expressly incorporated herein in their entireties by reference. In particular, U.S. Ser. Nos. 10/774,242; 11/811,002; 11/810,997; 11/986,058; 60/445,774; 60/811,568; and 60/836,365 are hereby expressly incorporated herein by reference in their entireties.

Although the presently disclosed inventive concept(s) and the advantages thereof have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the presently disclosed inventive concept(s) as defined in the present disclosure. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the processes, compositions of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure of the presently disclosed inventive concept(s), processes, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the presently disclosed inventive concept(s). Accordingly, the presently disclosed inventive concept(s) are intended to include within their scope all such processes, compositions of matter, means, methods, or steps.

REFERENCES

-   Cohen D. The plasminogen (fibrinolytic) system. Thromb. Haemost.     1999; 82:259-270. -   Wiman B, Cohen D. On the kinetics of the reaction between human     antiplasmin and plasmin. Eur. J Biochem. 1978; 84:573-578. -   Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human     plasma. Biochem. J. 1976; 159:545-553. -   Cohen D. Identification and some properties of a new fast-reacting     plasmin inhibitor in human plasma. Eur. J. Biochem. 1976;     69:209-216. -   Bangert K, Johnsen A H, Christensen U, Thorsen S. Different     N-terminal forms of alpha 2-plasmin inhibitor in human plasma.     Biochem. J. 1993; 291 (Pt 2):623-625. -   Koyama T, Koike Y, Toyota S et al. Different NH2-terminal form with     12 additional residues of alpha 2-plasmin inhibitor from human     plasma and culture media of Hep G2 cells. Biochem. Biophys. Res.     Commun. 1994; 200:417-422. -   Lee K N, Jackson K W, Christiansen V J, Chung K H, McKee P A. A     novel plasma proteinase potentiates alpha2-antiplasmin inhibition of     fibrin digestion. Blood 2004; 103:3783-3788. -   Lee K N, Jackson K W, Christiansen V J et al. Antiplasmin-cleaving     enzyme is a soluble form of fibroblast activation protein. Blood     2006; 107:1397-1404. -   Hirosawa S, Nakamura Y, Miura O, Sumi Y, Aoki N. Organization of the     human alpha 2-plasmin inhibitor gene. Proc. Natl. Acad. Sci. U.S.A     1988; 85:6836-6840. -   Holmes W E, Nelles L, Lijnen H R, Collen D. Primary structure of     human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J.     Biol. Chem. 1987; 262:1659-1664. -   Tone M, Kikuno R, Kume-Iwaki A, Hashimoto-Gotoh T. Structure of     human alpha 2-plasmin inhibitor deduced from the cDNA sequence. J.     Biochem. (Tokyo) 1987; 102:1033-1041. -   Lind B, Thorsen S. A novel missense mutation in the human plasmin     inhibitor (alpha2-antiplasmin) gene associated with a bleeding     tendency. Br. J. Haematol. 1999; 107:317-322. -   Wiman B. Affinity-chromatographic purification of human alpha     2-antiplasmin. Biochem. J. 1980; 191:229-232. -   Beebe D P, Aronson D L. An automated fibrinolytic assay performed in     microtiter plates. Thromb. Res. 1987; 47:123-128. -   Jones A J, Meunier A M. A precise and rapid microtitre plate clot     lysis assay: methodology, kinetic modeling and measurement of     catalytic constants for plasminogen activation during fibrinolysis.     Thromb. Haemost. 1990; 64:455-463. -   Lee K N, Lee S C, Jackson K W et al. Effect of     phenylglyoxal-modified alpha2-antiplasmin on urokinase-induced     fibrinolysis. Thromb. Haemost. 1998; 80:637-644. -   Tam J P. Synthetic peptide vaccine design: synthesis and properties     of a high-density multiple antigenic peptide system. Proc. Natl.     Acad. Sci. U.S.A 1988; 85:5409-5413. -   von Rokitansky C. Abnormal conditions of the arteries. A Manual of     Pathological Anatomy. London: Sydenham Society; 1852:261-275. -   Virchow R. Phlogose and Thrombose im Gefasssystem. In: Virchow R,     ed. Gesammelte Abhandlungen zur Wissenschatflichen Medizin.     Frankfurt: Meidinger Sohn & Co.; 1856:458-636. -   Smith E B. Fibrinogen, fibrin and fibrin degradation products in     relation to atherosclerosis. Clin. Haematol. 1986; 15:355-370. -   Jorgensen L. The role of platelets in the initial stages of     atherosclerosis. J. Thromb. Haemost. 2006; 4:1443-1449. -   Schwartz C J, Valente A J, Kelley J L, Sprague E A, Edwards E H.     Thrombosis and the development of atherosclerosis: Rokitansky     revisited. Semin. Thromb. Hemost. 1988; 14:189-195. -   Fuster V, Badimon L, Badimon J J, Chesebro J H. The pathogenesis of     coronary artery disease and the acute coronary syndromes (1). N.     Engl. J. Med. 1992; 326:242-250. -   Bini A, Kudryk B J. Fibrinogen in human atherosclerosis. Ann. N.Y.     Acad. Sci. 1995; 748:461-471. -   Bini A, Fenoglio J J, Jr., Mesa-Tejada R, Kudryk B, Kaplan K L.     Identification and distribution of fibrinogen, fibrin, and     fibrin(ogen) degradation products in atherosclerosis. Use of     monoclonal antibodies. Arteriosclerosis 1989; 9:109-121. -   Loscalzo J. The relation between atherosclerosis and thrombosis.     Circulation 1992; 86:11195-11199. -   Smith E B, Keen G A, Grant A, Stirk C. Fate of fibrinogen in human     arterial intima. Arteriosclerosis 1990; 10:263-275. -   Smith E B, Thompson W D. Fibrin as a factor in atherogenesis.     Thromb. Res. 1994; 73:1-19. -   White J G. Platelets and atherosclerosis. Eur. J. Clin. Invest 1994;     24 Suppl 1:25-29. -   Xiao Q Danton M J, Witte D P et al. Fibrinogen deficiency is     compatible with the development of atherosclerosis in mice. J. Clin.     Invest 1998; 101:1184-1194. -   Marutsuka K, Hatakeyama K, Yamashita A, Asada Y. Role of     thrombogenic factors in the development of atherosclerosis. J.     Atheroscler. Thromb. 2005; 12:1-8. -   Kathiresan S, Yang Q, Larson M G et al. Common genetic variation in     five thrombosis genes and relations to plasma hemostatic protein     level and cardiovascular disease risk. Arterioscler. Thromb. Vasc.     Biol. 2006; 26:1405-1412. -   Spurlock B O, Chandler A B. Adherent platelets and surface     microthrombi of the human aorta and left coronary artery: a scanning     electron microscopy feasibility study. Scanning Microsc. 1987;     1:1359-1365. -   Meade T W, Ruddock V, Stirling Y, Chakrabarti R, Miller G J.     Fibrinolytic activity, clotting factors, and long-term incidence of     ischaemic heart disease in the Northwick Park Heart Study. Lancet     1993; 342:1076-1079. -   Xiao Q, Danton M J, Witte D P et al. Plasminogen deficiency     accelerates vessel wall disease in mice predisposed to     atherosclerosis. Proc. Natl. Acad. Sci. U.S.A 1997; 94:10335-10340. -   Kwaan H C. Physiologic and pharmacologic implications of     fibrinolysis. Artery 1979; 5:285-290. -   Smith E B. Haemostatic factors and atherogenesis. Atherosclerosis     1996; 124:137-143. -   Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis     in atherosclerosis. Ann. Epidemiol. 1992; 2:427-438. -   Tanaka K, Sueishi K. The coagulation and fibrinolysis systems and     atherosclerosis. Lab Invest 1993; 69:5-18. -   Favier R, Aoki N, de M P. Congenital alpha(2)-plasmin inhibitor     deficiencies: a review. Br. J. Haematol. 2001; 114:4-10. -   Eda K, Ohtsuka S, Seo Y et al. Conservative treatment of hemolytic     complication following coil embolization in two adult cases of     patent ductus arteriosus. Jpn. Circ. J. 2001; 65:834-836. -   Levi M, Roem D, Kamp A M et al. Assessment of the relative     contribution of different protease inhibitors to the inhibition of     plasmin in vivo. Thromb. Haemost. 1993; 69:141-146. -   Harpel P C, Mosesson M W. Degradation of human fibrinogen by plasms     alpha2-macroglobulin-enzyme complexes. J. Clin. Invest 1973;     52:2175-2184. -   Aoki N, Harpel P C. Inhibitors of the fibrinolytic enzyme system.     Semin. Thromb. Hemost. 1984; 10:24-41.

TABLE 1 Cyclic Amines and Proline Analogs 4-hydroxypyrrolidine-2-carboxylic acid (cis and trans) 3-phenylpyrrolidine-2-carboxylic acid (cis and trans) 3-hydroxypyrrolidine-2-carboxylic acid (cis and trans) 4-hydroxypyrrolidine-2-carboxylic acid (cis and trans) 2-ethylthiazolidine-4-carboxylic acid (cis and trans) 2-methylthiazolidine-4-carboxylic acid (cis and trans) 2-phenylthiazolidine-4-carboxylic acid (cis and trans) 5,5-dimethylthiazolidine-4-carboxylic acid thiazolidine-2-carboxylic acid (cis and trans) thiazolidine-4-carboxylic acid (cis and trans) azetidine-2-carboxylic acid (cis and trans) thiazolidine-2-carboxylic acid (cis and trans) thiazolidine-4-carboxylic acid (cis and trans) amino-L-proline methyl ester cyano-L-proline methyl ester 4-cyano-L-proline 3,4-dehydro-L-proline Boronyl proline 4-fluoro-L-proline nitrileproline lysyl piperidide N-(4-chlorobenzyl)4-0x0-4-(1-piperidinyl)-1,3-(s)-butane-diamine bromocyclopentyl carboxylic acid chlorocyclopentyl carboxylic acid fluorocyclopentyl carboxylic acid cis-3-methylproline cis-3-ethylproline cis-3-isopropylproline cis-3-isopentanylproline homoproline benzyl-proline (2-fluoro-benzyl)-proline (3-fluoro-benzyl)-proline (4-fluoro-benzyl)-proline (2-chloro-benzyl)-proline (3-chloro-benzyl)-proline (4-chloro-benzyl)-proline (2-bromo-benzyl)-proline (3-bromo-benzyl)-proline (4-bromo-benzyl)-proline phenethyl-proline (2-methyl-benzyl)-proline (3-methyl-benzyl)-proline (4-methyl-benzyl)-proline (2-nitro-benzyl)-proline (3-nitro-benzyl)-proline (4-nitro-benzyl)-proline (1-Naphthalenylmethyl)-proline (2-Naphthalenylmethyl)-proline (2,4-dichloro-benzyl)-proline (3,4-dichloro-benzyl)-proline (3,4-difluoro-benzyl)-proline (2-trifluoromethyl-benzyl)-proline (3-trifluoromethyl-benzyl)-proline (4-trifluoromethyl-benzyl)-proline (2-cyano-benzyl)-proline (3-cyano-benzyl)-proline (4-cyano-benzyl)-proline (4-iodo-benzyl)-proline (3-Phenyl-allyl)-proline (3-Phenyl-allyl)-proline (3-Phenyl-propyl)-proline (4-tert-Butyl-benzyl)-proline Benzhydryl-proline (4-Biphenylmethyl)-proline (4-Thiazolylmethyl)-proline (3-Benzo[b]thiophenylmethyl)-proline (2-Thiophenylmethyl)-proline (5-Bromo-2-Thiophenylmethyl)-proline (3-Thiophenylmethyl)-proline (2-Furanylmethyl)-proline (2-Pyridinylmethyl)-proline (3-Pyridinylmethyl)-proline (4-Pyridinylmethyl)-proline Proline carbonitrile Allyl-proline Propynyl-proline 4-Phenyl-pyrrolidine-3-carboxylic acid 4-(2-fluoro-phenyl)-pyrrolidine-3-carboxylic acid 4-(3-fluoro-phenyl)-pyrrolidine-3-carboxylic acid trans-4-(4-fluoro-phenyl)-pyrrolidine-3-carboxylic acid trans-4-(2-chloro-phenyl)-pyrrolidine-3-carboxylic acid trans-4-(3-chloro-phenyl)-pyrrolidine-3-carboxylic acid 4-(4-chloro-phenyl)-pyrrolidine-3-carboxylic acid 4-(2-bromo-phenyl)-pyrrolidine-3-carboxylic acid 4-(3-bromo-phenyl)-pyrrolidine-3-carboxylic acid trans-4-(4-bromo-phenyl)-pyrrolidine-3-carboxylic acid 4-(2-methyl-phenyl)-pyrrolidine-3-carboxylic acid 4-(3-methyl-phenyl)-pyrrolidine-3-carboxylic acid 4-(4-methyl-phenyl)-pyrrolidine-3-carboxylic acid 4-(2-nitro-phenyl)-pyrrolidine-3-carboxylic acid 4-(3-nitro-phenyl)-pyrrolidine-3-carboxylic acid 4-(4-nitro-phenyl)-pyrrolidine-3-carboxylic acid 4-(1-naphthyl)-pyrrolidine-3-carboxylic acid 4-(2-naphthyl)-pyrrolidine-3-carboxylic acid 4-(2,5-dichloro-phenyl)-pyrrolidine-3-carboxylic acid 4-(2,3-dichloro-phenyl)-pyrrolidine-3-carboxylic acid 4-(2-trifluoromethyl-phenyl)-pyrrolidine-3-carboxylic acid 4-(3-trifluoromethyl-phenyl)-pyrrolidine-3-carboxylic acid 4-(4-trifluoromethyl-phenyl)-pyrrolidine-3-carboxylic acid 4-(2-cyano-phenyl)-pyrrolidine-3-carboxylic acid 4-(3-cyano-phenyl)-pyrrolidine-3-carboxylic acid 4-(4-cyano-phenyl)-pyrrolidine-3-carboxylic acid 4-(2-methoxy-phenyl)-pyrrolidine-3-carboxylic acid 4-(3-methoxy-phenyl)-pyrrolidine-3-carboxylic acid 4-(4-methoxy-phenyl)-pyrrolidine-3-carboxylic acid 4-(2-hydroxy-phenyl)-pyrrolidine-3-carboxylic acid 4-(3-hydroxy-phenyl)-pyrrolidine-3-carboxylic acid 4-(4-hydroxy-phenyl)-pyrrolidine-3-carboxylic acid 4-(2,3-dimethoxy-phenyl)-pyrrolidine-3-carboxylic acid 4-(3,4-dimethoxy-phenyl)-pyrrolidine-3-carboxylic acid 4-(3,5-dimethoxy-phenyl)-pyrrolidine-3-carboxylic acid 4-(2-pyridinyl)-pyrrolidine-3-carboxylic acid 4-(3-pyridinyl)-pyrrolidine-3-carboxylic acid 4-(6-methoxy-3-pyridinyl)-pyrrolidine-3-carboxylic acid 4-(4-pyridinyl)-pyrrolidine-3-carboxylic acid 4-(2-thienyl)-pyrrolidine-3-carboxylic acid 4-(3-thienyl)-pyrrolidine-3-carboxylic acid 4-(2-furanyl)-pyrrolidine-3-carboxylic acid 4-isopropyl-pyrrolidine-3-carboxylic acid pyrrolidides 2-nitrile pyrrolidine fluoropyrrolidine bromopyrrolidine chloropyrrolidine Pyrrolidinenitriles Piperidine Pyrrolidone Azetidine pipecolic acid Piperidide 3-carboxy-1,2,3,4-tetrahydro-isoquinoline 2-carboxy-2,3-dehydroindole cyclopentyls N-substituted cyclopentyl derivatives cyclohexyls N-substituted cyclohexyl derivatives val-boroPro glu-boroPro oxazolidine and proline analogs and derivatives as defined in U.S. Pat. No. 4,428,939; 6,890,904; 4,762,821 and Published Applications 2003/0158114; 20050272703; and 2006/0287245.

TABLE 2 APCE/FAP Inhibitor Compounds Number Compound 1 Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 2 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 3 Benzoyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 4 Benzyloxycarbonyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl- boroProline 5 Succinyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 6 Acetyl-β-homoArgininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 7 Acetyl-Lysinyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 8 Acetyl-β-homoLysinyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 9 Acetyl-Ornithinyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 10 Acetyl-Diaminopropionyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 11 Acetyl-Histidinyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-boroProline 12 Acetyl-Argininyl-(11-amino-3,6,9-Trioxaundecanoyl)-D-Alaninyl-boroProline 13 Acetyl-Argininyl-(12-amino-4,7,10-trioxadodecanoyl)-D-Alaninyl-boroProline 14 Acetyl-Argininyl-β-Alaninyl-β-Alaninyl-D-Alaninyl-boroProline 15 Acetyl-Argininyl-(6-aminohexanoyl)-D-Alaninyl-boroProline 16 Acetyl-Argininyl-(8-aminooctanoyl)-D-Alaninyl-boroProline 17 Acetyl-Argininyl-Glycinyl-Glycinyl-Glycinyl-D-Alaninyl-boroProline 18 Acetyl-Argininyl-Glycinyl-Glycinyl-Serinyl-D-Alaninyl-boroProline 19 Acetyl-Argininyl-Glutaminyl-Leucinyl-Threoninyl-Serinyl-D-Alaninyl- boroProline 20 Acetyl-Argininyl-Glycinyl-Glycinyl-boroProline 21 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-Serinyl-Glycinyl-boroProline 22 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-Glycinyl-boroProline 23 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Serinyl-boroProline 24 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-2-nitrile pyrrolidine 25 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-pyrrolidine-2- carbonitrile 26 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-prolinal 27 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-2-nitrile piperidine 28 Acetyl-Argininyl-(8-amino-3,6-Dioxaoctanoyl)-D-Alaninyl-2-nitrile-4-fluoro- pyrrolidine

Amino acids or amino acid derivatives or analogs may be either L- or D-form unless specified.

TABLE 3 Inhibition Constants of Various APCE/FAP Inhibitor Compounds Inhibitor # Structure^(a) Ki (μM)^(b) (1) FRQLTS-G pipecolinyl-NQEQV 14.0 ± 0.8 (2) FR-peg-G-pipecolinyl-NQEQV 14.8 ± 1.4 (3) FG-peg-G-pipecolinyl-NQEQV 57.1 ± 3.1 (4) FR-peg-G-pipecolinyl-NQGQV 14.5 ± 0.6 (5) FR-peg-G-pyrrolidide 67.7 ± 5.8 (6) FG-peg-G-pyrrolidide 703 ± 68 (7) FR-peg-pyrrolidide >1000 (8) FR-peg-G-[r]fluoropyrrolidide 53.8 ± 4.9 (9) FR-peg-G-[s]fluoropyrrolidide 55.3 ± 5.3 (10) FR-peg-G-piperidide 264 ± 23 (11) FR-peg-G-pipecolinamide >1000 ^(a)peg represents 8-amino-3,6-dioxaoctanoic acid, and [r] and [s] for different stereoconfigurations on the pyrrolidine ring. ^(b)Data represent the best-fit value ± the standard error, inhibition of APCE activity.

TABLE 4 APCE/FAP and DPPIV Inhibition Constants (Ki) Of Various Inhibitor Compounds APCE/FAP DPPIV Inhibitor Compound Ki (nM) Ki (nM) Selectivity Ac-Gly-L-boroPro 20.7 314 15.2 Ac-Arg-peg-Gly-DL-boroPro 3.1 1150 371 Ac-Arg-Gly-Gly-DL-boroPro 22.9 341 14.9 Ac-Arg-peg-D-Ala-D-boroPro 189 20480 108 Ac-Arg-peg-D-Ala-L-boroPro 5.7 6130 1075 Ac-Arg-peg-D-Ala-DL(25:75%)- 7.7 ND — boroPro Ac-Arg-peg-D-Ala-DL(50:50%)- 9.5 11170 1176 boroPro Ac-Arg-peg-D-Ala-DL(75:25%)- 18.3 ND — boroPro Ac-Arg-peg-D-Asp-L-boroPro 1377 7129 5.2 Ac-Arg-peg-Ser-Gly-L-boroPro 2.7 861 319 Ac-Arg-peg-Gly-L-boroPro 1.8 440 244 Ac-Arg-Gly-Gly-L-boroPro 17.2 322 18.7 Data represent the best-fit value ± the standard error, inhibition of APCE activity. Selectivity is expressed as Ki (DPPIV)/Ki (APCE/FAP) 

What is claimed is:
 1. A method of inhibiting activity of cell surface Fibroblast Activation Protein alpha (FAPα), comprising: exposing cells having cell surface FAPα to a compound having the formula: B-Xaa₁-Sp-Xaa₂-Cyc  (Formula I) wherein: B is a protecting group; Xaa₁ is a positively-charged amino-acid; Sp is a spacer molecule having a length in a range of 0.3 nm to 2.5 nm; Xaa₂ is a glycine, D-alanine, D-serine, or D-threonine; Cyc is boronyl proline or cyanopyrrolidine; and wherein the compound binds cell surface FAPα and inhibits the activity thereof.
 2. The method of claim 1, wherein Xaa₁ of the compound comprises α,β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine, β-homoornithine, arginine, β-homoarginine, homoarginine, lysine, homolysine, β-homolysine, or histidine.
 3. The method of claim 1, wherein Sp of the compound is selected from the group consisting of at least one of γ-aminobutyric acid; ε-aminocaproic acid; 8-amino-3,6-dioxaoctanoic acid; 11-amino-3,6,9-trioxaundecanoic acid; 14-amino-3,6,9,12-tetraoxatetradecanoic acid; α-aminobutyric acid; 5-aminopentanoic acid; 6-aminohexanoic acid; 7-aminoheptanoic acid; 8-aminooctanoic acid; 3-(aminooxy)acetic acid, β-alanine, glycine; alanine; threonine; tryptophan; tyrosine; methionine; leucine; isoleucine; valine; serine; proline; ethylene glycol; PEG_(n); propylene glycol; PPG_(n); amino-PEG_(n)-carboxy; amino-PPG_(n)-carboxy; and combinations thereof, and wherein n=1-6.
 4. The method of claim 1, wherein Sp of the compound is ethylene glycol, PEG_(n), propylene glycol, PPG_(n), amino-PEG_(n)-carboxy group or an amino-PPG_(n)-carboxy group, or any combination thereof, and wherein n=1-6.
 5. The method of claim 1, wherein Sp of the compound has a length in a range of 0.6 nm to 1.75 nm.
 6. The method of claim 1, wherein B of the compound is selected from the group consisting of: aminobenzoyl (Abz), acetyl (Ac), benzoyl (Bz), benzyloxycarbonyl (Z), t-Butyloxycarbonyl (Boc), Furylacryloyl (Fa), Methoxysuccinyl (MeOSuc), Pyroglutamate (Pyr), Phenylalanine, Succinyl (Suc), and any combination of 1-3 natural amino acids.
 7. The method of claim 1, wherein Xaa₂ of the compound is D-alanine or D-serine.
 8. The method of claim 1, wherein the cells are cancer cells or myofibroblast cells.
 9. The method of claim 1, wherein the compound is disposed in a pharmaceutically acceptable carrier or vehicle.
 10. The method of claim 1, wherein the compound has a Ki<20 nM for FAPα and a Ki>200 nM for dipeptidylpeptidase IV (DPPIV).
 11. The method of claim 1, wherein the compound comprises an isostere bond between Xaa₁ and Sp.
 12. The method of claim 1, wherein the compound comprises a 1-10mer peptide or oligopeptide extending from Cyc in the C-terminal direction.
 13. The method of claim 1, wherein the compound has a Ki (DPPIV):Ki (APCE/FAP) ratio>500.
 14. The method of claim 1, wherein the cells are provided in vitro.
 15. The method of claim 1, wherein the cells are in vivo. 